Compound
curcumin
A yellow-orange dye obtained from tumeric, the powdered root of curcuma longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.
Studied for
39 endpoints · 139 findings · 61 papers · 43 null
- Tumour necrosis factor alpha concentrationlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Aspartate aminotransferaselowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Body mass indexlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- C-reactive protein concentrationlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Interleukin-6 concentrationlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Structure
A β-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.
Loading the model…
- Class
- Organic compound
- Formula
- C21H20O6
- Mass
- 368.385 g/mol
- Charge
- 0
- InChIKey
- VFLDPWHFBUODDF-FCXRPNKRSA-N
- SMILES
- COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence.
What the evidence says
How to read these marks139 findings · 39 endpoints · 61 papers · 43 null · by evidence strength
- Evidence strength
- Strong
- Moderate
- Limited
- Very limited
- Insufficient
What moved
96 findings
Decreases LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Furthermore, at the end of the study, the Curcumin group reported lower LDL levels ( P = 0.024) and higher HDL levels ( P = 0.024) versus the control group.”
Quoted verbatim from Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.. - Study
- RCT
- Dose
- Oral Puritan's Pride Turmeric Curcumin 500 mg capsules (Curcuma longa root 450 mg plus turmeric extract 50 mg standardised to 95% curcuminoids), one capsule three times daily after meals (1500 mg/day) for 14 weeks, added to conventional therapy
- Population
- Adults aged 50-74 y with type 2 diabetes and a 10-year ASCVD risk score >=5%, Cairo, Egypt; 85 randomised (42 curcumin, 43 control), 72 analysed (36 per group); open-label trial in which the control arm received conventional therapy only, with no placebo; the paper declares no primary endpoint and powered its sample size on change in HDL-C; LDL-C calculated by the Friedewald equation, HDL-C by enzymatic colorimetric assay
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.2025PMID:40759997Permalink
Decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The overall pooling of data indicated that curcumin supplementation was significantly associated with reduced AST with MD (95% CI) of −3.90 (−5.97, −1.82) units/L, although high heterogeneity was observed (I2 = 73.9%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 15 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -3.9 mean difference, 95% CI -5.97 to -1.82
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
Decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“The overall effect estimates from the meta-analysis demonstrated a significant reduction in CRP in curcumin compared to placebo, SMD = −0.59, 95%CI (−1.11, −0.07), p = 0.03.”
Quoted verbatim from Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.. - Study
- meta-analysis
- Population
- adults with type 2 diabetes
Effect -0.59 standardised mean difference, 95% CI -1.11 to -0.07
Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.2024PMID:39683570Permalink
Increases superoxide dismutase activity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); SOD by RANSOD colorimetric assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases interleukin-6 concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The combined effect size for curcumin supplementation in reducing IL-6 levels was MD = -0.33, indicating a substantial improvement.”
Quoted verbatim from Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status.. - Study
- meta-analysis
- Population
- trained and untrained adults undergoing muscle-damaging exercise
Effect -0.33 mean difference
Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status.2024PMID:39008500Permalink
Decreases erythrocyte sedimentation rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“We found a conflicting effect of curcumin supplementation on systemic inflammation markers, with a significantly large decrease in the ESR but not in the CRP level ( Table 2).”
Quoted verbatim from A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms.. - Study
- meta-analysis
- Population
- patients with knee osteoarthritis; inflammation-marker outcome pooled across the curcumin trials (placebo and active comparators), all studies and timepoints
A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms.2022PMID:35458170Permalink
Show the remaining 90
Decreases disease Activity Score in 28 joints (DAS-28)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The pooled analysis demonstrated that curcumin supplementation significantly reduced DAS28 compared with controls (WMD = –1.47, 95% CI [–1.68,–1.26]) (Fig. A).”
Quoted verbatim from Effect of curcumin on inflammatory markers and disease activity in patients with rheumatoid arthritis: A meta-analysis.. - Study
- meta-analysis
- Population
- adults with rheumatoid arthritis
Effect -1.47 mean difference, 95% CI -1.68 to -1.26
Effect of curcumin on inflammatory markers and disease activity in patients with rheumatoid arthritis: A meta-analysis.2025PMID:41327719Permalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Anthropometric measurements, including BMI and WC, were significantly lower in the curcumin group compared to the placebo group at 3, 6, 9, and 12 months ( Table 4; B).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; this outcome is named in neither the declared primary nor the declared secondary endpoint list (declared primary outcome: liver steatosis by controlled attenuation parameter); BMI by bioelectrical impedance analyser (Omron HBF-362)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Increases adverse event occurrence (oral or enteral supplement)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Meta-analysis of adverse reactions associated with curcumin indicated a statistically significant increase in adverse events compared to placebo (SMD = 2.40, 95 % CI: 1.37 to 4.21, I2 = 44.1 %) (Supplementary 4 - SFigure 3).”
Quoted verbatim from Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults in randomised trials of oral curcumin supplementation for cognitive ageing; secondary endpoint
Effect 2.4 standardised mean difference, 95% CI 1.37 to 4.21
Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.2025PMID:40579315Permalink
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The results showed that curcumin reduced HOMA-IR compared with placebo [WMD = -0.28, 95% CI (-0.36, -0.20), P < 0.00001].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 343
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.28 mean difference, 95% CI -0.36 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Thirteen studies assessed reduction of BMI indicating curcumin supplementation was effective in lowering BMI with MD (95% CI) of −0.34 (−0.62, −0.05) kg/m2; I2 = 62.7%, see Supplementary Appendix Q.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 13 RCTs; BMI was an additional (secondary) outcome of this review
Effect -0.34 mean difference, 95% CI -0.62 to -0.05
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
Decreases visual analogue scale pain intensity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The PVAS was much lower in the curcumin group than in the placebo groups (overall mean differences and CI: −2.04 and −2.85, −1.24; P <.00001).”
Quoted verbatim from Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.. - Study
- meta-analysis
- Population
- adults with osteoarthritis or rheumatoid arthritis; curcumin vs placebo, pain visual analogue score
Effect -2.04 mean difference, 95% CI -2.85 to -1.24
Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.2016PMID:27533649Permalink
Increases total antioxidant capacity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“TAS levels were significantly higher in the curcumin group than in the placebo group (1.85 [1.74–1.95] vs. 1.65 [1.55–1.79], p < 0.001), with a large effect size ( r = 0.72, 95% CI: 0.61–0.81).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months; total antioxidant status reported in micromol trolox equivalent/L
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Curcumin resulted a significant reduction in BMI (SMD −0.37; 95% CI, −0.61, −0.13; P < 0.01), weight (SMD −0.23; 95% CI, −0.39, −0.06; P < 0.01), and WC levels (SMD −0.25; 95% CI, −0.44, −0.05; P = 0.01).”
Quoted verbatim from The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome and related disorders, compared to placebo (pooled random-effects meta-analysis)
Effect -0.37 standardised mean difference, 95% CI -0.61 to -0.13
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2019PMID:31249528Permalink
Increases glutathione peroxidase activity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); GPx by RANSEL colorimetric assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Conversely, MDA levels, a marker of lipid peroxidation, were significantly lower in the curcumin group compared with placebo (1.29 [1.05–1.58] vs. 2.45 [2.14–2.77], p < 0.001), corresponding to a large effect size ( r = 0.85, 95% CI: 0.77–0.91).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
Decreases interleukin-6 concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Median IL-6 levels were markedly lower in the curcumin group than in the placebo group (5.50 [4.39–9.00] vs. 13.69 [11.27–15.65], p < 0.001), with a large effect size ( r = 0.78, 95% CI: 0.68–0.86).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“In parallel, curcumin treatment led to a significant reduction in malondialdehyde (MDA) levels—a key biomarker of oxidative stress—across the same time points (Table 3).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The results showed that curcumin reduced ALT compared with placebo [SMD = -0.55, 95% CI (-1.01, -0.09), P = 0.02].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 639
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.55 standardised mean difference, 95% CI -1.01 to -0.09
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
Decreases serum leptin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The results showed that curcumin intake among individuals with metabolic diseases significantly reduced leptin (SMD −0.97; 95% CI, −1.18, −0.75; P < 0.001) and increased adiponectin levels (SMD 1.05; 95% CI, 0.23, 1.87; P = 0.01).”
Quoted verbatim from The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- individuals with metabolic diseases, compared to placebo (pooled meta-analysis)
Effect -0.97 standardised mean difference, 95% CI -1.18 to -0.75
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2019PMID:31249528Permalink
Decreases delayed-onset muscle soreness
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The combined effect size for curcumin supplementation in mitigating muscle soreness registers at mean difference (MD) = -0.61, signifying a substantial reduction in pain, particularly in cases of lower back pain.”
Quoted verbatim from Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status.. - Study
- meta-analysis
- Population
- trained and untrained adults undergoing muscle-damaging exercise
Effect -0.61 mean difference
Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status.2024PMID:39008500Permalink
Decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The results showed that curcumin reduced AST compared with placebo [SMD = -0.48, 95% CI (-0.76, -0.20), P = 0.0007].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 681
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.48 standardised mean difference, 95% CI -0.76 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
Decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Similarly, the mean AST reduction was − 15.03 ± 16.31 U/L in the nanocurcumin group and − 0.92 ± 11.64 U/L in the placebo group, with a significant between-group difference ( P = 0.004).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.. - Study
- RCT
- Dose
- Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
- Population
- Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; baseline AST was higher in the nano-curcumin arm than in the placebo arm (38.44 vs 27.21 U/L, P = 0.05); serum AST by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink
Decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Compared with placebo, curcumin treatment significantly reduced FPG and HbA1c (key markers of diabetes progression) at 6, 9, and 12 months (Table 4; C).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint, significant at 6, 9, 12 months
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases tumour necrosis factor alpha concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×5“Curcumin significantly reduced the pro-inflammatory biomarkers IL-1β and TNF-α, (Table 3).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“Curcumin supplementation resulted in a significant reduction in total cholesterol and LDL-C levels when compared to the placebo group at the 6, 9, and 12-month time points.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The overall pooling indicated that curcumin supplementation was significantly associated with reduced ALT [MD (95% CI) of −5.61 (−9.37, −1.85) units/L] with moderate heterogeneity observed (I2 = 64.3%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 14 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -5.61 mean difference, 95% CI -9.37 to -1.85
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“In contrast, nanocurcumin significantly increased total antioxidant capacity (SMD: 1.60; 95% CI: 0.93 to 2.31) and reduced malondialdehyde levels (SMD: -1.93; 95% CI: -3.19 to -0.66), indicating a robust antioxidative effect.”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 153
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The means of HOMA-IR of the curcumin-treated group were lower than those of placebo group at all follow-up visits (3, 6, and 9 months).”
Quoted verbatim from Curcumin extract for prevention of type 2 diabetes.. - Study
- RCT
- Duration
- 9 months
- Dose
- curcumin extract capsules, 250 mg curcuminoids per capsule, 6 capsules/day (1500 mg/day) for 9 months
- Population
- adults with prediabetes
Curcumin extract for prevention of type 2 diabetes.2012PMID:22773702Industry fundedPermalink
Increases total antioxidant capacity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); total antioxidant capacity by the automated Erel assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Increases total antioxidant capacity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“In contrast, nanocurcumin significantly increased total antioxidant capacity (SMD: 1.60; 95% CI: 0.93 to 2.31) and reduced malondialdehyde levels (SMD: -1.93; 95% CI: -3.19 to -0.66), indicating a robust antioxidative effect.”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 153
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“The results showed that curcumin reduced BMI compared with placebo [weighted mean difference (WMD) = -0.49, 95% CI (-0.81, -0.18), P = 0.002].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 462
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.49 mean difference, 95% CI -0.81 to -0.18
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
Decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“The results showed that compared with the control group, the CRP in curcumin was lower [WMD=-0.35 95%CI (-0.55, -0.15), P=0.0005].”
Quoted verbatim from Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with rheumatoid arthritis
Effect -0.35 mean difference, 95% CI -0.55 to -0.15
Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials.2023PMID:37033930Permalink
Increases HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Furthermore, at the end of the study, the Curcumin group reported lower LDL levels ( P = 0.024) and higher HDL levels ( P = 0.024) versus the control group.”
Quoted verbatim from Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.. - Study
- RCT
- Dose
- Oral Puritan's Pride Turmeric Curcumin 500 mg capsules (Curcuma longa root 450 mg plus turmeric extract 50 mg standardised to 95% curcuminoids), one capsule three times daily after meals (1500 mg/day) for 14 weeks, added to conventional therapy
- Population
- Adults aged 50-74 y with type 2 diabetes and a 10-year ASCVD risk score >=5%, Cairo, Egypt; 85 randomised (42 curcumin, 43 control), 72 analysed (36 per group); open-label trial in which the control arm received conventional therapy only, with no placebo; the paper declares no primary endpoint and powered its sample size on change in HDL-C; LDL-C calculated by the Friedewald equation, HDL-C by enzymatic colorimetric assay
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.2025PMID:40759997Permalink
Decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“The overall evidence showed a statistically significant reduction in FBG in the T2D group from curcumin compared to placebo MD = −11.48 mg/dL, 95%CI (−14.26, −8.70), p < 0.01.”
Quoted verbatim from Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.. - Study
- meta-analysis
- Population
- adults with type 2 diabetes
Effect -11.48 mean difference, 95% CI -14.26 to -8.7
Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.2024PMID:39683570Permalink
Decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Twelve studies assessed reduction of FBS indicating curcumin supplementation was associated with a significant reduction in FBS, with MD (95% CI) of −2.05 (−3.08, −1.01) mg/dL, I2 = 0%, see Supplementary Appendix O.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 12 RCTs; glycaemic indices were an additional (secondary) outcome of this review, not a liver endpoint
Effect -2.05 mean difference, 95% CI -3.08 to -1.01
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
Decreases glycated haemoglobin (HbA1c)
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×2“Compared with placebo, curcumin treatment significantly reduced FPG and HbA1c (key markers of diabetes progression) at 6, 9, and 12 months (Table 4; C).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint, significant at 6, 9, 12 months
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
Decreases body mass
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×1“Curcumin resulted a significant reduction in BMI (SMD −0.37; 95% CI, −0.61, −0.13; P < 0.01), weight (SMD −0.23; 95% CI, −0.39, −0.06; P < 0.01), and WC levels (SMD −0.25; 95% CI, −0.44, −0.05; P = 0.01).”
Quoted verbatim from The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome and related disorders, compared to placebo (pooled random-effects meta-analysis)
Effect -0.23 standardised mean difference, 95% CI -0.39 to -0.06
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2019PMID:31249528Permalink
Increases superoxide dismutase activity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“There was a significant reduction in circulating MDA concentrations (SMD = -0.769, 95% CI: -1.059 to -0.478) and a significant increase in SOD activity (SMD = 1.084, 95% CI: 0.487 to 1.680) following curcumin supplementation.”
Quoted verbatim from Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.. - Study
- meta-analysis
- Population
- adults in RCTs of curcumin supplementation (>=4 weeks) assessing oxidative-stress biomarkers
Effect 1.084 standardised mean difference, 95% CI 0.487 to 1.68
Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.2018PMID:30527253Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Quantitative data synthesis revealed a significant effect of curcuminoids vs. placebo in reducing circulating CRP concentrations (weighed mean difference: -2.20 mg/L; 95% confidence interval [CI]: -3.96, -0.44; p = 0.01).”
Quoted verbatim from Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.. - Study
- meta-analysis
- Population
- meta-analysis of randomized controlled trials of curcuminoids measuring circulating CRP concentration
Effect -2.2 mean difference, 95% CI -3.96 to -0.44
Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.2015PMID:25618800Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Combined effect sizes suggested a significant effect of curcumin supplementation on reduced body weight (BW) (WMD: -0.94 kg, 95% CI: -1.40, -0.47) and body mass index (BMI) (WMD: -0.40 kg/m2, 95% CI: -0.60, -0.19), respectively.”
Quoted verbatim from The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with metabolism-related diseases, dose-effect meta-analysis of 31 RCTs
The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.2023PMID:35475714Permalink
Decreases serum leptin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Meta-analysis showed a significant decrease in plasma leptin concentrations following curcumin treatment (standardized mean difference: -0.69, 95% confidence interval: -1.16, -0.23, p = 0.003; I2 = 76.53%).”
Quoted verbatim from Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis.. - Study
- meta-analysis
- Population
- adults (mixed populations pooled across curcumin RCTs measuring leptin)
Effect -0.69 standardised mean difference, 95% CI -1.16 to -0.23
Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis.2017PMID:28880413Permalink
Decreases aspartate aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.2025PMID:38213188Permalink
Increases serum adiponectin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“The pooled results showed that curcumin supplementation significantly increased adiponectin concentrations in comparison with placebo (WMD: 0.82 Hedges' g; 95% confidence interval (CI): 0.33 to 1.30, P˂0.001).”
Quoted verbatim from The effect of curcumin supplementation on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults, pooled across 6 RCTs (652 subjects) of curcumin supplementation vs placebo
Effect 0.82 standardised mean difference, 95% CI 0.33 to 1.3
The effect of curcumin supplementation on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials.2019PMID:31425942Permalink
Increases flow-mediated dilation
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“We found a significant increase in flow-mediated dilation (FMD) following curcumin supplementation (WMD: 1.49; 95% CI [0.16, 2.82]).”
Quoted verbatim from The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults, pooled across 10 studies (11 effect sizes) of curcumin supplementation for endothelial function
Effect 1.49 mean difference, 95% CI 0.16 to 2.82
The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials.2019PMID:31423626Permalink
Increases HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Beyond that, Curcumin intake significantly increased high-density lipoprotein cholesterol (HDL-C) levels (ES: 1.34 mg/dl, 95% CI: 0.37, 2.31, p = 0.007; I2 = 97.8%, p < 0.001).”
Quoted verbatim from Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.. - Study
- meta-analysis
- Population
- adults, umbrella meta-analysis of 19 meta-analyses
Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.2022PMID:36058763Permalink
Decreases aspartate aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Our results indicate that curcumin did not affect serum alanine aminotransferase, but it did reduce aspartate aminotransferase levels.”
Quoted verbatim from Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.. - Study
- meta-analysis
- Population
- patients with non-alcoholic fatty liver disease (NAFLD)
Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.2024PMID:38965866Permalink
Increases flow-mediated dilation
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“This meta-analysis of 5 randomized clinical trials indicates a significant effect of curcumin preparations to increase the FMD compared to placebo and thus endothelial function.”
Quoted verbatim from Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis.. - Study
- meta-analysis
- Population
- adults, pooled across 5 RCTs of curcumin preparations vs placebo
Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis.2020PMID:32101871Permalink
Decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2022PMID:35345991Permalink
Decreases total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2022PMID:35345991Permalink
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“There was a significant reduction of circulating TNF-α concentrations following curcumin supplementation (WMD: -4.69pg/mL, 95% CI: -7.10, -2.28, p<0.001).”
Quoted verbatim from Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials.. - Study
- meta-analysis
- Population
- adults across 8 RCTs of curcumin supplementation (disease population not specified in abstract)
Effect -4.69 mean difference, 95% CI -7.1 to -2.28
Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials.2016PMID:27025786Permalink
Decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.2025PMID:38213188Permalink
Decreases total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“This meta-analysis has shown that curcuminoid therapy significantly reduces plasma triglycerides and increases HDL-C levels.”
Quoted verbatim from Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of curcuminoids
Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials.2019PMID:29185808Permalink
Decreases LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Curcumin supplementation significantly reduced BMI, BW, and WC with mean differences (MDs) of -0.24 kg/m2 (95% CI: -0.32, -0.16 kg/m2), -0.59 kg (95% CI: -0.81, -0.36 kg), and -1.32 cm (95% CI: -1.95, -0.69 cm), respectively.”
Quoted verbatim from The effect of curcumin supplementation on weight loss and anthropometric indices: an umbrella review and updated meta-analyses of randomized controlled trials.. - Study
- meta-analysis
- Population
- Adults pooled across 50 randomised controlled trials of curcumin supplementation versus control, in an updated meta-analysis carried out alongside an umbrella review of 14 prior systematic reviews. 21 of the 50 trials were judged at high risk of bias; the estimate pools plain and bioavailability-enhanced curcumin formulations.
The effect of curcumin supplementation on weight loss and anthropometric indices: an umbrella review and updated meta-analyses of randomized controlled trials.2023PMID:36898635Permalink
Decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“Between-group comparison suggested significantly greater reductions in serum concentrations of TNF-α, IL-6, TGF-β and MCP-1 in the curcumin versus placebo group (p<0.001).”
Quoted verbatim from Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- curcumin 1 g/day for 8 weeks
- Population
- adults with metabolic syndrome (NCEP-ATPIII criteria), post-hoc analysis
Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.2016PMID:27470399Permalink
Increases serum adiponectin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“In conclusion, curcumin supplementation significantly increased circulating adiponectin and decreased leptin levels in adults.”
Quoted verbatim from The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Population
- adults
The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.2024PMID:37980942Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Curcumin supplementation was associated with lower hs-CRP concentrations (MD = -1.06 mg/L; 95% CI -1.97 to -0.16; p = 0.030; I2 = 17.3%), although sensitivity analyses involving unit-ambiguous or statistically reconstructed data increased uncertainty.”
Quoted verbatim from Effects of Curcumin Supplementation on Inflammatory Biomarkers in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with T2DM
Effect -1.06 mean difference, 95% CI -1.97 to -0.16
Effects of Curcumin Supplementation on Inflammatory Biomarkers in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42797011Permalink
Increases serum adiponectin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038Permalink
Decreases hamilton Depression Rating Scale (HDRS) total score
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Chronic supplementation with curcumin produced significant antidepressant behavioral response in depressed patients by reduction of 17-item Hamilton Depression Rating Scale and Montgomery-Asberg Depression Rating Scale scores.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)
Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.2015PMID:26066335Permalink
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“Furthermore, curcumin decreases inflammatory cytokines interleukin 1β and tumor necrosis factor α level, increases plasma brain-derived neurotrophic factor levels, and decreases salivary cortisol concentrations compared with placebo group.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)
Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.2015PMID:26066335Permalink
Decreases cortisol concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Furthermore, curcumin decreases inflammatory cytokines interleukin 1β and tumor necrosis factor α level, increases plasma brain-derived neurotrophic factor levels, and decreases salivary cortisol concentrations compared with placebo group.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)
Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.2015PMID:26066335Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.”
Quoted verbatim from Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Population
- adults with type 2 diabetes, reassessed from a prior 3-month curcuminoids RCT cohort
Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.2014PMID:25374024Permalink
Decreases malondialdehyde (circulating)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Furthermore, synthesized data from three studies indicated that curcumin was associated with reduced levels of MDA, a marker of lipid peroxidation (MD = -1.99, 95% CI = -3.22 to -0.77, p = 0.001;.”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.. - Study
- animal · not in humans
- Population
- ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 3 studies
Effect -1.99 mean difference, 95% CI -3.22 to -0.77
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
Decreases visual analogue scale pain intensity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“The NMA results showed that compared with placebo, curcumin significantly reduced the visual analogue scale pain score (MD = -1.63, 95% CI: -2.91 to -0.45) and total WOMAC score (MD = -18.85, 95% CI: -29.53 to -8.76).”
Quoted verbatim from Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis.. - Study
- meta-analysis
- Population
- Patients with knee osteoarthritis; Bayesian network meta-analysis, the contrast recorded here is curcumin monotherapy versus placebo. The review included 23 studies and 2175 KOA patients across 6 interventions overall; the abstract does not state how many patients or trials fed this particular pairwise estimate. The abstract does not state the VAS anchors, the scale length, or the recall frame.
Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis.2024PMID:38036015Permalink
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.”
Quoted verbatim from Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Population
- adults with type 2 diabetes, reassessed from a prior 3-month curcuminoids RCT cohort
Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.2014PMID:25374024Permalink
Increases superoxide dismutase activity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Curcuminoids supplementation also significantly increased serum superoxide dismutase (SOD) activity.”
Quoted verbatim from Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Population
- adults with type 2 diabetes, reassessed from a prior 3-month curcuminoids RCT cohort
Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.2014PMID:25374024Permalink
Decreases pulse wave velocity (segment unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038Permalink
Decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients.”
Quoted verbatim from Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Dose
- 300 mg/day
- Population
- overweight/obese adults with type 2 diabetes (BMI ≥ 24; fasting glucose ≥ 7.0 mmol/L or postprandial glucose ≥ 11.1 mmol/L)
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.2013PMID:22930403Permalink
Decreases glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients.”
Quoted verbatim from Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Dose
- 300 mg/day
- Population
- overweight/obese adults with type 2 diabetes (BMI ≥ 24; fasting glucose ≥ 7.0 mmol/L or postprandial glucose ≥ 11.1 mmol/L)
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.2013PMID:22930403Permalink
Decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients.”
Quoted verbatim from Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Dose
- 300 mg/day
- Population
- overweight/obese adults with type 2 diabetes (BMI ≥ 24; fasting glucose ≥ 7.0 mmol/L or postprandial glucose ≥ 11.1 mmol/L)
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.2013PMID:22930403Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“As for the lipid profile parameters, serum triglycerides were significantly reduced following curcumin supplementation (p = 0.009).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
Decreases catalase activity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.”
Quoted verbatim from Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 1 g/d
- Population
- male Iranian veterans with sulphur mustard-induced chronic pruritus
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.2012PMID:22099425Permalink
Decreases blood urea nitrogen
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After the treatment of MRL. lpr female mice (8–10 weeks old) with curcumin at 1 g/kg bodyweight, daily for 2 months, we found that 24-h proteinuria and serum BUN levels were significantly reduced compared to the placebo group, p < 0.05.”
Quoted verbatim from Curcumin Attenuates Both Acute and Chronic Immune Nephritis.. - Study
- animal · not in humans
- Duration
- 2 months
- Dose
- 1 g/kg body weight daily by oral gavage
- Population
- female MRL.lpr lupus mice aged 8-10 weeks, curcumin or sesame-oil placebo daily for 2 months
Curcumin Attenuates Both Acute and Chronic Immune Nephritis.2020PMID:32143311Permalink
Decreases total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect -0.73 standardised mean difference, 95% CI -1.32 to -0.13
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect -1.21 standardised mean difference, 95% CI -1.78 to -0.65
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
Decreases malondialdehyde (circulating)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“There was a significant reduction in circulating MDA concentrations (SMD = -0.769, 95% CI: -1.059 to -0.478) and a significant increase in SOD activity (SMD = 1.084, 95% CI: 0.487 to 1.680) following curcumin supplementation.”
Quoted verbatim from Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.. - Study
- meta-analysis
- Population
- adults in RCTs of curcumin supplementation (>=4 weeks) assessing oxidative-stress biomarkers
Effect -0.769 standardised mean difference, 95% CI -1.059 to -0.478
Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.2018PMID:30527253Permalink
Decreases aspartate aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.”
Quoted verbatim from Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Population
- adults with type 2 diabetes, reassessed from a prior 3-month curcuminoids RCT cohort
Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.2014PMID:25374024Permalink
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“There was a significant reduction of circulating IL-6 concentrations following curcuminoids supplementation (WMD: -0.60pg/mL, 95% CI: -1.06, -0.14, p=0.011).”
Quoted verbatim from Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults in 9 RCTs (10 treatment arms) receiving curcuminoids supplementation compared with placebo
Effect -0.6 mean difference, 95% CI -1.06 to -0.14
Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials.2016PMID:27392742Permalink
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Between-group comparison suggested significantly greater reductions in serum concentrations of TNF-α, IL-6, TGF-β and MCP-1 in the curcumin versus placebo group (p<0.001).”
Quoted verbatim from Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- curcumin 1 g/day for 8 weeks
- Population
- adults with metabolic syndrome (NCEP-ATPIII criteria), post-hoc analysis
Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.2016PMID:27470399Permalink
Inhibits TLR4
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“However, the increase in TLR4 expression induced by LPS was attenuated after intra-articular administration of curcumin (P<0.05; P<0.01).”
Quoted verbatim from Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis.. - Study
- animal · not in humans
- Duration
- 8 weeks
- Dose
- 50 μl of 1 mg/mL curcumin intra-articular once a week for 8 weeks
- Population
- cartilage and synovium of rats with ACLT-induced osteoarthritis stimulated with intra-articular LPS; mRNA by real-time PCR and protein by western blot
Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis.2019PMID:31432995Permalink
Decreases serum leptin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.. - Study
- RCT
- Duration
- 6 months
- Population
- adults with type 2 diabetes
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.2014PMID:24445038Permalink
Decreases aspartate aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2022PMID:35345991Permalink
Decreases body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Curcumin supplementation significantly reduced BMI (weighted mean difference [WMD] = -0.34 kg/m2 , 95% CI [-0.64, -0.04], p < .05) and WC (WMD = -2.12 cm, 95% CI [-3.26, -0.98], p < .001).”
Quoted verbatim from The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with nonalcoholic fatty liver disease (NAFLD), pooled across 8 RCTs (520 participants)
Effect -0.34 mean difference, 95% CI -0.64 to -0.04
The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.2020PMID:31799714Permalink
Decreases body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×6“Combined effect sizes suggested a significant effect of curcumin supplementation on reduced body weight (BW) (WMD: -0.94 kg, 95% CI: -1.40, -0.47) and body mass index (BMI) (WMD: -0.40 kg/m2, 95% CI: -0.60, -0.19), respectively.”
Quoted verbatim from The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with metabolism-related diseases, dose-effect meta-analysis of 31 RCTs
The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.2023PMID:35475714Permalink
Decreases glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
Decreases serum leptin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“In conclusion, curcumin supplementation significantly increased circulating adiponectin and decreased leptin levels in adults.”
Quoted verbatim from The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Population
- adults
The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.2024PMID:37980942Permalink
Decreases interleukin-6 concentration
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×6“As expected, the ELISA results showed that the concentrations of the ds-DNA antibody, IL-6 and IFN-γ were notably lower in the curcumin treatment group than in the control group.”
Quoted verbatim from Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 50 mg/kg daily, intraperitoneal, dissolved in DMSO
- Population
- MRL/lpr lupus mice treated daily with curcumin or vehicle for 2 weeks; serum measured by ELISA
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway.2024PMID:39053932Permalink
Decreases interleukin-6 concentration
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×6“Regarding pro-inflammatory cytokines, the results from four studies showed that curcumin treatment led to a significant reduction in IL-6 concentrations (SMD = -2.59, 95% CI = -4.32 to -0.86, p = 0.003).”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.. - Study
- animal · not in humans
- Population
- ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 4 studies
Effect -2.59 standardised mean difference, 95% CI -4.32 to -0.86
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
Decreases tumour necrosis factor alpha concentration
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×5“Furthermore, a meta-analysis of three studies suggested that curcumin significantly suppressed TNF-α levels (MD = -71.01, 95% CI = -98.65 to -43.37, p < 0.001).”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.. - Study
- animal · not in humans
- Population
- ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 3 studies
Effect -71.01 mean difference, 95% CI -98.65 to -43.37
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
Inhibits TRAF6
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“As shown in, curcumin inhibited TRAF6 protein expression in OCPs in a concentration-dependent manner in the presence of RANKL.”
Quoted verbatim from Curcumin suppresses RANKL-induced osteoclast precursor autophagy in osteoclastogenesis by inhibiting RANK signaling and downstream JNK-BCL2-Beclin1 pathway.. - Study
- in vitro · not in humans
- Dose
- 0, 5, 10 or 15 μM
- Population
- mouse bone marrow-derived osteoclast precursors (OCPs) cultured with M-CSF and RANKL; western blot
Curcumin suppresses RANKL-induced osteoclast precursor autophagy in osteoclastogenesis by inhibiting RANK signaling and downstream JNK-BCL2-Beclin1 pathway.2024PMID:37179010Permalink
Decreases serum creatinine concentration
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Consistently, treatment with curcumin significantly decreased the level of serum creatinine compared to that in the vehicle group.”
Quoted verbatim from Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 50 mg/kg daily, intraperitoneal, dissolved in DMSO
- Population
- MRL/lpr lupus mice treated daily with curcumin or vehicle for 2 weeks; serum creatinine measured by ELISA
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway.2024PMID:39053932Permalink
What did not
43 findings
No detected effect on visual analogue scale pain intensity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In the between-group analysis, no significant differences were observed in VAS hand pain at rest, VAS hand pain during activity, VAS hand morning stiffness, DASH score, hand grip, pinch strength and rescue drug usage at 1, 3, and 6 months.”
Quoted verbatim from Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial.. - Study
- RCT
- Participants
- 27
- Dose
- 170 mg/day curcuminoids (turmeric powder capsules, 28.75 mg curcuminoids per capsule, two capsules three times daily) for 3 months
- Population
- patients over 50 years with hand osteoarthritis, pain during activity, between-group at 1, 3 and 6 months
Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial.2025PMID:41053771Permalink
No detected effect on systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.29 mean difference, 95% CI -0.91 to 0.34
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
No detected effect on diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“Meta‐analysis of 16 effect sizes demonstrated no significant alteration in DBP following supplementation of curcumin/turmeric compared to control groups (WMD: −1.20 mmHg; 95% CI: −2.84 to 0.44; p = 0.15) (Figure.”
Quoted verbatim from Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.. - Study
- meta-analysis
- Population
- adults with prediabetes or type 2 diabetes; primary endpoint
Effect -1.2 mean difference, 95% CI -2.84 to 0.44
Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.2026PMID:41388744Permalink
No detected effect on diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.02 mean difference, 95% CI -0.55 to 0.52
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
No detected effect on withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There was no difference between patients receiving curcuminoids and those receiving placebo with regard to incidence of treatment withdrawal due to adverse events (RR: 0.90 [95% CI: 0.21, 3.79]).”
Quoted verbatim from Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults with knee osteoarthritis; curcuminoid vs placebo; safety endpoint
Effect 0.9 risk ratio, 95% CI 0.21 to 3.79
Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis.2018PMID:29622343Permalink
No detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2“However, curcumin was not significantly associated with HbA1c based on pooling three included studies with MD (95% CI) of −0.24 (−0.66, 0.18) %, I2 = 85.8%, see Supplementary Appendix P.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 3 RCTs pooled; glycaemic indices were an additional (secondary) outcome of this review
Effect -0.24 mean difference, 95% CI -0.66 to 0.18
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
Show the remaining 37
No detected effect on serum alkaline phosphatase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“There was no significant association between curcumin supplement and ALP [MD (95% CI) of −8.88 (−24.68, 6.93) units/L].”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 6 RCTs, all using bioavailability-enhanced curcumin forms; liver enzymes were a primary outcome of interest
Effect -8.88 mean difference, 95% CI -24.68 to 6.93
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
No detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In contrast, the fasting blood glucose levels remained the same in both the curcumin ( p = 0.154, 95% CI: −7.547 to 0.976) and placebo group ( p > 0.999, 95% CI: −5.537 to 5.093).”
Quoted verbatim from Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 80 mg curcumin (Longvida lipophilic matrix), one capsule daily
- Population
- adults aged 60 years or older with prediabetes or overweight/obesity; co-primary endpoint
Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.2025PMID:40647269Permalink
No detected effect on serum alkaline phosphatase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“The mean change in ALP levels was − 0.77 ± 14.54 U/L in the nanocurcumin group and − 5.57 ± 20.37 U/L in the placebo group, with no significant difference between groups in the crude analysis ( P = 0.262).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.. - Study
- RCT
- Dose
- Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
- Population
- Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; the between-group difference remained non-significant after adjustment for baseline values, age, sex, diabetes, calorie intake change and BMI (P = 0.161); serum ALP by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink
No detected effect on carotid-femoral pulse wave velocity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There was no group by time interaction for aortic PWV (P=0.8), carotid artery compliance (P=0.2), or other arterial stiffness parameters (all P>0.2).”
Quoted verbatim from Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress.. - Study
- RCT
- Duration
- 3 months
- Dose
- 2000 mg/day Longvida® curcumin (~400 mg curcumin), once daily for 12 weeks
- Population
- healthy middle-aged and older adults, 45-74 years
Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress.2017PMID:28070018Permalink
No detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×4“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 10 trials
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
No detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 11 trials
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
No detected effect on triglycerides
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 373
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
No detected effect on glycated haemoglobin (HbA1c)
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×2“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 336
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
No detected effect on alanine aminotransferase
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“A comparison of aspartate transaminase, alanine transaminase, and creatinine levels revealed no significant differences between the curcumin and placebo groups.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, safety assessment
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
No detected effect on C-reactive protein concentration
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×2“No statistically significant reduction in C-reactive protein was observed (SMD: -0.78; 95% CI: -1.58 to 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 303
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
No detected effect on aspartate aminotransferase
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“A comparison of aspartate transaminase, alanine transaminase, and creatinine levels revealed no significant differences between the curcumin and placebo groups.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, safety assessment
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
No detected effect on fasting blood glucose
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 389
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
No detected effect on serum creatinine concentration
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“A comparison of aspartate transaminase, alanine transaminase, and creatinine levels revealed no significant differences between the curcumin and placebo groups.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; prespecified safety/adverse-effect assessment, not an efficacy endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
No detected effect on systolic blood pressure (setting unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“Curcumin was not associated with a significant change in waist circumference measurement (p = 0.6) and systolic blood pressure level (p = 0.269).”
Quoted verbatim from Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with metabolic syndrome
Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials.2019PMID:30941814Permalink
No detected effect on superoxide dismutase activity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Though, curcumin supplementation had no significant effect on tumor necrosis factor-alpha (SMD -1.62; 95% CI [-3.60, 0.36]; p = 0.10) and superoxide dismutase levels (SMD 0.34; 95% CI [-1.06, 1.74], p = 0.63).”
Quoted verbatim from The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults
Effect 0.34 standardised mean difference, 95% CI -1.06 to 1.74
The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials.2019PMID:30402990Permalink
No detected effect on tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“Though, curcumin supplementation had no significant effect on tumor necrosis factor-alpha (SMD -1.62; 95% CI [-3.60, 0.36]; p = 0.10) and superoxide dismutase levels (SMD 0.34; 95% CI [-1.06, 1.74], p = 0.63).”
Quoted verbatim from The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults
Effect -1.62 standardised mean difference, 95% CI -3.6 to 0.36
The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials.2019PMID:30402990Permalink
No detected effect on body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“Although curcumin intervention could not change tumor neurosis factor-α (TNF-α) concentration (SMD = -0.3; 95% CI: -0.7 to 0.04; p = 0.08, I2 = 25.3%, 3 studies, 153 participants), when compared with the placebo group.”
Quoted verbatim from The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 153
- Population
- hemodialysis patients
The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis.2022PMID:36205586Permalink
No detected effect on HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on systolic blood pressure (setting unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on diastolic blood pressure (setting unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
No detected effect on alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Our results indicate that curcumin did not affect serum alanine aminotransferase, but it did reduce aspartate aminotransferase levels.”
Quoted verbatim from Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.. - Study
- meta-analysis
- Population
- patients with non-alcoholic fatty liver disease (NAFLD)
Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.2024PMID:38965866Permalink
No detected effect on total antioxidant capacity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, curcumin did not significantly change total antioxidant capacity (TAC) (ES = 0.29; 95 % CI: -0.09, 0.66, P= 0.059).”
Quoted verbatim from The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses.. - Study
- meta-analysis
- Population
- adults in randomized clinical trials of curcumin supplementation
The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses.2024PMID:38945354Permalink
No detected effect on serum alkaline phosphatase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.2025PMID:38213188Permalink
No detected effect on HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“Plasma HDL-cholesterol and TG concentrations remained unchanged across all groups.”
Quoted verbatim from Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 200 mg/day
- Population
- hypercholesterolaemic adults; 2×2 factorial trial (placebo, phytosterols 2 g/d, curcumin 200 mg/d, or phytosterols+curcumin combined), result reported across all four trial arms
Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.2018PMID:29291429Permalink
No detected effect on total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
No detected effect on body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, no significant effects of curcumin supplementation on body weight were found.”
Quoted verbatim from The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with nonalcoholic fatty liver disease (NAFLD), pooled across 8 RCTs (520 participants)
The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.2020PMID:31799714Permalink
No detected effect on HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect 0.28 standardised mean difference, 95% CI -0.22 to 0.77
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
No detected effect on serum alkaline phosphatase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“Concerning bone formation and mineral metabolism, pooled estimates from seven studies revealed that curcumin did not significantly alter ALP levels (SMD = -1.00, 95% CI = -3.14 to 1.13, p = 0.36).”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.. - Study
- animal · not in humans
- Population
- ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 7 studies
Effect -1 standardised mean difference, 95% CI -3.14 to 1.13
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
No detected effect on interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Also, curcumin supplementation elicited significant improvements in MVC [WMD = 3.10 nm, 95% CI (1.45-4.75)] and ROM [WMD = 6.49°, 95% CI (3.91-9.07)], although no significant changes in IL-6 and IL-8 levels were found.”
Quoted verbatim from The effect of curcumin supplementation on delayed-onset muscle soreness, inflammation, muscle strength, and joint flexibility: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults, dose-response meta-analysis of 10 RCTs (exercise-induced muscle damage)
The effect of curcumin supplementation on delayed-onset muscle soreness, inflammation, muscle strength, and joint flexibility: A systematic review and dose-response meta-analysis of randomized controlled trials.2022PMID:35574627Permalink
What it touches on the way
Mechanistic reach
2 entities
2 entities reached.
0 reported hops2 assembled from the scaffold
Reactions
3 reactions
CHEBI:67263+2NADP(3-)curcumin+2NADPH(4-)+2hydron
Reaction pageDirection not assertedBalanced
Rhea RHEA:34815CC BY 4.0Reference data
CHEBI:67262+NADP(3-)curcumin+NADPH(4-)+hydron
Reaction pageDirection not assertedBalanced
Rhea RHEA:34819CC BY 4.0Reference data
CHEBI:142389+CHEBI:87305+watercurcumin+carbon dioxide+2coenzyme A(4-)
Reaction pageDirection not assertedBalanced
Rhea RHEA:34823CC BY 4.0Reference data
On the label
Labelled products
390 products
Source: NIH DSLD · Ingredient: curcumin · 390 products · Declared amount per serving: 4–1,500 mg (367 products)
375 labels state an amount15 do not
- 1MDCurcuminMD+Curcuma longa · Longvida Optimized Curcumin extract (Form: from Curcuma longa PlantPart: root Genus: Curcuma Species: longa)400 mgper 1 Capsule(s)DSLD:246733
- 1MDCurcuminMD+Turmeric rhizome extract400 mgper 1 Capsule(s)DSLD:274797
- 360 Health Solutions MediCleanseCurcuma longa extract400 mgper 53.3 Gram(s)DSLD:45528
- Absorb HealthLiposomal Curcumin160 mgper 0.167 Oz(s)DSLD:215803
- AdvoCareCore Nutrition SystemBCM-95 extract200 mgper 1 4-Packet Strip(s)DSLD:177397
- AFI America's FinestCurcumin C3 ReductTurmeric Rhizome Extract · 95% Tetrahydrocurcuminoids400 mgper 2 Capsule(s)DSLD:275492
- Alive By NatureLSG Resveratrol/Curcumin75 mgper 2 mLDSLD:230824
- ALLMAXALLFLEXCurcuma longa, Powder100 mgper 2 Capsule(s)DSLD:325773
- AOR Advanced Orthomolecular Research AdvancedAdvanced Muscle EaseCurcuma longa80 mgper 3 Capsule(s)DSLD:214424
- AOR Advanced Orthomolecular Research AdvancedCurcuMINDCurcuma longa · LongVida Optimized Curcumin (Form: from Curcuma longa PlantPart: root Genus: Curcuma Species: longa)1,455 mgper 1 Capsule(s)DSLD:214569
- AOR Advanced Orthomolecular Research AdvancedCurcuVIVACurcuma longa400 mgper 1 Capsule(s)DSLD:214576
- AOR Advanced Orthomolecular Research AdvancedInfla-KnightCurcuma longa · LongVida Optimized Curcumin (Form: from Curcuma longa PlantPart: root Genus: Curcuma Species: longa)240 mgper 1 Capsule(s)DSLD:214648
Show the remaining 378
- AOR Advanced Orthomolecular Research PremiumCurcumin-95Turmeric Extract · Curcumin (Form: from Turmeric extract)1,200 mgper 3 Capsule(s)DSLD:214563
- AOR Advanced Orthomolecular Research UltraCurcumin UltraCurcuminoid-Galactomannan Complex · CurQfen Curcumin (Form: from Curcuminoid-Galactomannan Complex)153 mgper 1 Softgel(s)DSLD:214573
- aProvenProductBang! Brain Healthcurcominoids · Curcumin (Form: standaardized to 95% curcominoids)75 mgper 4 Capsule(s)DSLD:29884
- Aurora NutrascienceexoFlex50 mgper 2 tspDSLD:79050
- Aurora NutrascienceMega-Liposomal Curcumin 600 mg600 mgper 1 TbspDSLD:66619
- Aurora NutrascienceMicro-Pack+ exoFlex +Plus Vitamin CCurcumin50 mgper 10 mLDSLD:314564
- Aurora NutraScienceMega-Liposomal Curcumin+ 450 mg Organic Fruit FlavorCurcumin450 mgper 15 mLDSLD:276655
- Axe & Sledge SupplementsDaily CleanseCurcuma longa100 mgper 4 Capsule(s)DSLD:307177
- BeachbodyP90XCurcuminoids · Curcumin (Form: 95% Curcuminoids)100 mgper 6 Capsule(s)DSLD:42193
- BetterYouTurmeric Daily Oral Spray Natural Orange Flavor27 mgper 0.76 mLDSLD:313022
- Beyond HealthCurcumin Formula250 mgper 1 Capsule(s)DSLD:306886
- Bio NutritionCurcumin 500Turmeric · Curcumin (Form: from Turmeric Note: 95%)250 mgper 1 Vegetable Capsule(s)DSLD:200648
- Bio NutritionJoint WellnessCurcumin Note: 95%200 mgper 2 Capsule(s)DSLD:200588
- Bio NutritionTestosterone Wellness for MenCurcumin extract Note: 95%10 mgper 2 Tablet(s)DSLD:200614
- BiochemW+ 100% Whey Isolate Protein Infla-SupportCurcuminoids · UltraSOL Curcumin powder (Form: min 20% Curcuminoids (Form: Turmeric extract PlantPart: rhizome Genus: Curcuma Species: longa) Note: equal to 80 mg)400 mgper 25.1 Gram(s)DSLD:183729
- Bioclinic NaturalsBioLivX50 mgper 2 Capsule(s)DSLD:20891
- Bioclinic NaturalsTheracurmin-Pro 300Total Curcuminoids · Theracurmin(TM) (Form: surface controlled particle dispersion of turmeric root [curcuma longa] extract providing 90% total curcuminoids Genus: curcuma Species: longa)300 mgper 1 Capsule(s)DSLD:20796
- BioGanixTurmeric Curcumin With BioPerine 1000 mg1,000 mgper 2 Capsule(s)DSLD:70027
- BioSpec NutritionalsInflam-RxCurcuminoids · Curcumin Root Extract (Form: standardized to 95% curcuminoids) PlantPart: Root1,200 mgper 6 Veggie Capsule(s)DSLD:27756
- BiotiviaBio SpanCurcumin Note: 95% standardized extract150 mgper 1 Vegetarian Capsule(s)DSLD:58303
- Blackstone LabsOrthobolicCurcuminoids · Curcumin (Form: 95% Curcuminoids, Sodium Caprylate)150 mgper 2 Capsule(s)DSLD:204987
- Blueprint Bryan JohnsonNAC Ginger CurcuminCurcuminoids · std. 85% curcuminoids250 mgper 3 Veggie Capsule(s)DSLD:328207
- BronsonTurmeric Extract Curcumin C3 ReductTurmeric Rhizome Extract · standardized for 95% Tetrahydrocurcuminoids100 mgper 1 Capsule(s)DSLD:258169
- CarotecCurcumin/Boswellia1,500 mgper 3 Softgel(s)DSLD:282131
- ChiroNutraceuticalImmune Support100 mgper 2DSLD:277294
- ChromaDexTru Niagen ImmuneCurcuma longa30 mgper 1 Vegetarian Capsule(s)DSLD:323172
- CodeageGLP-Advantage+Turmeric · std. to 95% curcuminoids200 mgper 2 Capsule(s)DSLD:333409
- Codeage NanofoodCurcumin Phytosome 1000 mg CitrusCurcuma longa Root Extract500 mgper 1 mLDSLD:298436
- Core Med ScienceLiposomal CurcuminTurmeric500 mgper 2 Capsule(s)DSLD:291893
- Core NutritionalsSootheCurcuminoids1,000 mgper 6 Capsule(s)DSLD:269441
- Core Nutritionals LifelineHEARTCurcuminoids500 mgper 6 Capsule(s)DSLD:269426
- Country LifeSuper 10 AntioxidantTurmeric · Curcumin (Form: from Turmeric PlantPart: rhizome)100 mgper 2 Tablet(s)DSLD:13178
- Country LifeSuper 10 Antioxidantproviding100 mgper 2 Tablet(s)DSLD:326841
- Country LifeTime Release Malic Relief Formula200 mgper 2 Tablet(s)DSLD:14048
- CybergenicsPost Workout Citrus16 mgper 2 Gummy(ies)DSLD:307850
- CymbiotikaInflammatory HealthPhytoSure-O.C. · organic102.25 mgper 2 Vegetarian Capsule(s)DSLD:336104
- DaVinci Benefits LineAmyloid BenefitsCurcuma longa400 mgper 3 Capsule(s)DSLD:313203
- DaVinci Benefits LinePhyto BenefitsCurcuma longa root extract100 mgper 1 Capsule(s)DSLD:322193
- DaVinci Benefits LinePhyto BenefitsCurcuma longa root extract100 mgper 1 Capsule(s)DSLD:322194
- DaVinci LaboratoriesAmyloid CompleteCurcuma longa · Longvida Optimized Curcumin extract (Form: from Curcuma longa PlantPart: root Genus: Curcuma Species: longa)400 mgper 3 Capsule(s)DSLD:313206
- DaVinci LaboratoriesCX-2 SolutionCurcuma longa root extract250 mgper 3 Capsule(s)DSLD:303904
- DaVinci LaboratoriesEnz-Flameyielding200 mgper 9 Gram(s)DSLD:322164
- DaVinci LaboratoriesMetabolic MultiCurcuma longa root extract50 mgper 6 Capsule(s)DSLD:313228
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:244861
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:265739
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:266845
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:266848
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:267011
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:267012
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:267019
- DCCurcumin 950950 mgper 2 Capsule(s)DSLD:267020
- Doctor SchuhmacherCholesterol Formula500 mgper 3 Veggie Capsule(s)DSLD:277525
- Doctor's BestCurcumin Phytosome with MerivaCurcumin Phytosomeamount not statedper 2 Veggie Capsule(s)DSLD:302651
- Doctor's BestCurcumin Phytosome with MerivaCurcumin Extract · Standardized to contain min. 18% total Curcuminoids (180mg) Phospholipid complex from sunflower lecithin1,000 mgper 2 Veggie Capsule(s)DSLD:302652
- Doctor's BestHigh Absorption Curcumin 1000 mg1,000 mgper 1 Tablet(s)DSLD:302672
- Doctors' PreferredFocal Point Plus Fast-ActingCurcuma longa Rhizome Extract400 mgper 1 Capsule(s)DSLD:309890
- Douglas LaboratoriesDIM Enhanced125 mgper 1 Vegetarian Capsule(s)DSLD:231880
- Douglas LaboratoriesDIM Enhanced with Curcumin, Green Tea and Wasabia125 mgper 1 Vegetarian Capsule(s)DSLD:245464
- Douglas LaboratoriesDIM Enhanced with Curcumin, Green Tea and Wasabia125 mgper 1 Vegetarian Capsule(s)DSLD:245468
- Douglas LaboratoriesDIM Enhanced With Curcumin, Green Tea and Wasabia125 mgper 1 Vegetarian Capsule(s)DSLD:245982
- Douglas LaboratoriesDIM With Curcumin, Green Tea and WasabiaCurcuminoids · Curcumin Extract (Form: standardized to 95% Curcuminoids) PlantPart: root Genus: Curcuma Species: longa600 mgper 2 Vegetarian Capsule(s)DSLD:10451
- Douglas LaboratoriesMethylated Resveratrol PlusCurcuma longa extract250 mgper 1 Vegetarian Capsule(s)DSLD:232282
- Douglas LaboratoriesMethylated Resveratrol PlusCurcuma longa extract250 mgper 1 Vegetarian Capsule(s)DSLD:274083
- Douglas LaboratoriesMood Systems BalanceCurcuma longa200 mgper 2 Vegetarian Capsule(s)DSLD:232761
- Douglas LaboratoriesMood Systems BalanceCurcuma longa200 mgper 2 Vegetarian Capsule(s)DSLD:261903
- Douglas LaboratoriesMood Systems BalanceCurcuma longa200 mgper 2 Vegetarian Capsule(s)DSLD:273715
- Douglas LaboratoriesOptimized Curcumin with NeurophenolCurcuma longa · Longvida Optimized Curcumin extract (Form: from Curcuma longa PlantPart: rhizomes Genus: Curcuma Species: longa)400 mgper 2 Vegetarian Capsule(s)DSLD:230540
- Douglas LaboratoriesOptimized Curcumin With NeurophenolCurcuma longa400 mgper 2 Vegetarian Capsule(s)DSLD:62898
- Douglas LaboratoriesPack #1, Joint Health PackTetrahydrocurcuminoids · Standardized Curcumin Extract (Form: 95% Tetrahydrocurcuminoids) PlantPart: root150 mgper 1 Packet(s)DSLD:31413
- Douglas LaboratoriesPack #1, Joint Health PackTetrahydrocurcuminoids · Standardized Curcumin Extract (Form: 95% Tetrahydrocurcuminoids) PlantPart: root150 mgper 1 Packet(s)DSLD:31417
- Douglas LaboratoriesResvera-GoldTetrahydrocurcuminoids · Standardized Curcumin Extract (Form: 95% Tetrahydrocurcuminoids) PlantPart: root150 mgper 2 Capsule(s)DSLD:30683
- Dr. Julian Cano, N.D., LAcNK Defense50 mgper 2 Capsule(s)DSLD:333271
- Dr. SinatraFocal Point PlusCurcuma longa400 mgper 1 Capsule(s)DSLD:286042
- Dr. SinatraNattoPlus50 mgper 2 Capsule(s)DSLD:201842
- Dr. WhitakerTriveratrol Plus200 mgper 2 Capsule(s)DSLD:61964
- Ecological FormulasCurcumin With Zingerone & SaffronTurmeric root extract80 mgper 1 Capsule(s)DSLD:22325
- Ee Essential elementsGlucosamine Chondroitin95%60 mgper 1 Capsule(s)DSLD:275162
- EguooMilk Thistle & Co Q1010 mgper 1 Capsule(s)DSLD:321847
- Elevation HealthElevation Ultraplex Detox Nutrient PackCurcuma longa extract200 mgper 6 Capsule(s)DSLD:63604
- Elevation HealthUltraplex Mediclear-SGS Chocolate Flavored400 mgper 53.3 Gram(s)DSLD:63680
- Elevation HealthUltraplex Meriva 500-SF1 Gram(s)per 1 Capsule(s)DSLD:63678
- Enzyme Science(PEA)+Curcumin Phytosome Phosphatidylcholine Complex · 18-22% Curcuminoids500 mgper 2 Capsule(s)DSLD:334812
- Enzyme Science(PEA)+Curcumin Phytosome Phosphatidylcholine Complex · 18-22% Curcuminoids500 mgper 2 Capsule(s)DSLD:334813
- ETST Earth Science TechImmune Support100 mgper 2 Capsule(s)DSLD:70541
- Exir USATurmeric CurcuminTurmeric extract400 mgper 2 Capsule(s)DSLD:263874
- FREZZORCollagen Protein Broth Curcumin Chiliamount not statedper 20 Gram(s)DSLD:320795
- FREZZORSuperfood Raw Energy Natural Unflavoredamount not statedper 20 Gram(s)DSLD:320813
- Genestra BrandsCurcumin ComplexCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)400 mgper 1 Capsule(s)DSLD:211295
- Genestra BrandsMetabolic Protein ChocolateTurmeric · Curcumin (Form: from Turmeric PlantPart: rhizome)25 mgper 30.2 Gram(s)DSLD:231461
- Genestra BrandsMetabolic Protein VanillaTurmeric · Curcumin (Form: from Turmeric PlantPart: rhizome)25 mgper 25.2 Gram(s)DSLD:218086
- Genestra BrandsNeurogen CognitionLongvida Optimized Curcumin Note: providing400 mgper 2 Capsule(s)DSLD:228496
- Genestra BrandsPEA GI SupportCurcuma longa100 mgper 3 Capsule(s)DSLD:267731
- Genestra BrandsPhosCholine ComplexTurmeric · Curcumin (Form: from Turmeric PlantPart: rhizome)100 mgper 2 Tablet(s)DSLD:239087
- Genestra BrandsPro Pea BalanceCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)12.5 mgper 11.5 Gram(s)DSLD:55891
- Genestra BrandsPro Pea Balance Natural Chocolate FlavorCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)12.5 mgper 14 Gram(s)DSLD:55881
- GNC Preventive NutritionTotal Cleanser - AM Packet140 mgper 2 Yellow Tablet(s)DSLD:82600
- Gottfried InstituteHormone Balancing DetoxCurcuma longa extract200 mgper 6 Capsule(s)DSLD:45497
- Gottfried InstituteHormone Balancing EssentialsCurcuma longa extract · Curcumin Phytosome (Form: Curcuma longa extract PlantPart: root Genus: Curcuma Species: longa, Phosphatidylcholine Complex) Note: These ingredients are complexed with Time-Sorb(R), a time-release matrix.50 mgper 1 Packet(s)DSLD:45504
- Green Organic SupplementsLyme Disease Immune System EnhancerTurmeric · Organic, Organic, ext. 95%120 mgper 3 Vcap(s)DSLD:335150
- Greens TodayJoint Formula French Vanilla Flavor50 mgper 15 Gram(s)DSLD:11568
- Hard RhinoCurcumin 95% Turmeric ExtractTurmeric extract · Curcumin (Form: 95% Turmeric extract)1 Gram(s)per 1 Gram(s)DSLD:72249
- Hard RhinoCurcumin 95% Turmeric ExtractTurmeric extract · Curcumin (Form: 95% Turmeric extract)1,000 mgper 1 Gram(s)DSLD:72253
- Harvest NaturalsOsteoPointTurmeric Root Extract · standardized to 95% tetrahydrocurcuminoids200 mgper 5 Capsule(s)DSLD:321621
- Health Thru NutritionCurcu-GelTotal Curcuminoids Complex · Total curcuminoids complex with325 mgper 1 Softgel(s)DSLD:304836
- Health Thru Nutrition NaturallyPhysician's MultiVitamin FormulaTurmeric powder10 mgper 1 Caplet(s)DSLD:177596
- Healthy Choice NaturalsImmune EssentialsCurcumin Note: powder100 mgper 2 Capsule(s)DSLD:72032
- Healthy ItemsCMO PlusTurmeric Extract300 mgper 6 Capsule(s)DSLD:259071
- Healthy ItemsLiposomal Can-Help75 mgper 15 mLDSLD:259070
- Healthy ItemsLiposomal Can-Help Complex500 mgper 1 TbspDSLD:231116
- Healthy ItemsLiposomal CurcuminTurmeric root extract · Curcumin (Form: 95% Turmeric root extract PlantPart: root)166 mgper 1 tspDSLD:231070
- Healthy ItemsLiposomal Pain-Less250 mgper 1 TbspDSLD:11444
- HerbadietCurcuminBis-Desmethoxy Curcumin · Curcumin extract powder (Form: standardized to contain minimum 95% Curcuminoids-Curcumin, Bis-Desmethoxy Curcumin, Desmethoxy Curcumin)400 mgper 400 mgDSLD:244440
- HerbadietCurcumin + PiperineBis-Desmethoxy Curcumin · Curcumin extract powder (Form: standardized to contain minimum 95% Curcuminoids-Curcumin, Bis-Desmethoxy Curcumin, Desmethoxy Curcumin)385 mgper 400 mgDSLD:244249
- HyperbioticsPro-MenRoot Extract250 mgper 1 Tablet(s)DSLD:270251
- Igennus Healthcare NutritionLongvida Optimised Curcumin 500 mgTurmeric500 mgper 1 Capsule(s)DSLD:249447
- IheerboLiver Protection95%50 mgper 1 Tablet(s)DSLD:322681
- ImmunovitesTheracurmin BIDTurmeric · enhanced bioavailability water-dispersible600 mgper 1 Capsule(s)DSLD:315859
- InnovixLabsHigh Absorption Turmeric CurcuminTurmeric Rhizome Extract225 mgper 2 Tablet(s)DSLD:334985
- Integrative TherapeuticsClinical Nutrients HP Iron-Freeenhanced bioavailable water-dispersible Curcumin extract100 mgper 2 Capsule(s)DSLD:322138
- Integrative TherapeuticsCuralieveCurcumin · Enhanced bioavailable, amorphous450 mgper 2 Capsule(s)DSLD:317369
- Integrative TherapeuticsCuralieveCurcumin · enhanced bioavailable, amorphous curcumin450 mgper 2 Capsule(s)DSLD:317370
- Integrative TherapeuticsGlutamine Forte Lemon Lime FlavoredTurmeric (Curcuma longa) rhizome Complex · Theracurmin (Form: enhanced bioavailability water-dispersible Turmeric (Curcuma longa) rhizome Complex PlantPart: rhizome Genus: Curcuma Species: longa)100 mgper 6.7 Gram(s)DSLD:223190
- Integrative TherapeuticsGlutamine Forte Lemon Lime FlavoredCurcumin · enhanced bioavailable water-dispersible100 mgper 6.7 Gram(s)DSLD:269912
- Integrative TherapeuticsGlycation ManagerTurmeric · Theracurmin (Form: water-dispersible Turmeric) PlantPart: rhizome Genus: Curcuma Species: longaamount not statedper 2 Capsule(s)DSLD:64787
- Integrative TherapeuticsPro-Somenhanced bioavailable water-dispersible Curcumin extract100 mgper 2 Capsule(s)DSLD:256227
- Integrative TherapeuticsProthrivers Wellness BrainCurcumin · Enhanced Bioavailable Water-Dispersible75 mgper 2 Capsule(s)DSLD:265961
- Integrative TherapeuticsProthrivers Wellness Flavonoid Complexenhanced bioavailable water-dispersible Curcumin extract50 mgper 2 Capsule(s)DSLD:265969
- Intelligent LabsCurcumin 500Curcuma longa Root Extract · std. to contain 18-22% curcuminoids1 Gram(s)per 1 Capsule(s)DSLD:329232
- Irwin NaturalsCurcumin Pro-ActiveTurmeric Rhizome Extract150 mgper 2 Liquid Softgel(s)DSLD:292127
- Irwin NaturalsMax-Active BoswelliaTurmeric Rhizome Extract150 mgper 2 Liquid Soft-Gel(s)DSLD:323289
- IVLCurcumend Plus500 mgper 2 Vegetable Capsule(s)DSLD:248512
- IVLCurcumend Plus1,000 mgper 4 Capsule(s)DSLD:306997
- IVLTurmeric and Ginger Gummies Mango FlavoredTurmeric Rhizome Extract · standardized for 95% curcuminoids260 mgper 2 Gummy(ies)DSLD:307021
- Jacked FactoryPro-Series JointCurcuma longa500 mgper 2 Capsule(s)DSLD:257848
- Jarrow FormulasCurcumin Phytosome 500 mgCurcuma longa · complex500 mgper 1 Capsule(s)DSLD:307579
- Jigsaw HealthA.M.Total Curcuminoids · Curcumin C3 Complex (Form: NLT 95% Total Curcuminoids) PlantPart: rhizomes Genus: Curcuma Species: longa500 mgper 1 AM Packet(s)DSLD:270634
- Jigsaw HealthCurcumin C3 ComplexCurcuminoids · NLT 95% total curcuminoids500 mgper 1 Capsule(s)DSLD:334966
- Jigsaw HealthJigsaw BasicCurcuma longa500 mgper 1 Packet(s)DSLD:270489
- Jigsaw HealthP.M.Total Curcuminoids · Curcumin C3 Complex500 mgper 1 Packet(s)DSLD:270635
- Joy NutritionPremium CBD Softgels Curcumin Formula10 mgper 1 Softgel(s)DSLD:250198
- KAPPA NUTRITIONVitamin C Ginger Curcumin 4 in 1 Advanced ComplexCurcuma longa · 95% Curcuminoids (Equivalent to 7000 mg dried Fruit)200 mgper 2 Capsule(s)DSLD:272730
- KarunaBromInj1,200 mgper 4 Tablet(s)DSLD:23870
- KarunaBromlnjCurcuma longa1,200 mgper 4 Tablet(s)DSLD:327081
- KarunaMSM PlusCurcuma longa · standardized to 95% curcumin200 mgper 2 Capsule(s)DSLD:327120
- KarunaVegeGlucosamine PlusCurcumin · Curcumin (Form: standardized to 95% Curcumin) Genus: Curcuma Species: longa300 mgper 6 Capsule(s)DSLD:25077
- LidtkeL-TryptophanTurmeric150 mgper 1 Capsule(s)DSLD:257272
- Lidtke TryptoGOLDL-Tryptophan CompleteTurmeric · Curcumin (Form: as 95% Turmeric root PlantPart: root)150 mgper 1 Capsule(s)DSLD:257230
- Lidtke TryptoGOLDL-Tryptophan CompleteTurmeric · 95% Turmeric150 mgper 1 Capsule(s)DSLD:261021
- Life RenewKnee + Joint RenewCurcuma longa500 mgper 2 Capsule(s)DSLD:218324
- Life RenewMobility Support OptimizerCurcumin Phytosome500 mgper 1 Capsule(s)DSLD:218323
- LifeLinkPriMeric 593333 mgper 1 Capsule(s)DSLD:11755
- LifeSeasons EssentialsMeriva Curcumin Phytosome 500 mgCurcumin Phytosome500 mgper 2 Capsule(s)DSLD:310505
- Little DaVinciEnzflame Kids Powdered Drink Mixyielding200 mgper 9 Gram(s)DSLD:322165
- Marine Technology CorpAlgoran Inner-Healthnano300 mgper 2 Capsule(s)DSLD:309881
- Marine Technology CorpAlgoran Lifeforce300 mgper 2 Capsule(s)DSLD:247503
- Mary Ruth'sTurmeric & DHA Liposomal Orange GingerTurmeric rhizome extract520 mgper 15 mLDSLD:327736
- Mass ProbioticsGoLive Probiotic + Prebiotic Tangerine Turmeric250 mgper 9.6 Gram(s)DSLD:229458
- Mass ProbioticsGoLive Probiotic + Prebiotic Turmeric with Mango & Ginger250 mgper 8 Gram(s)DSLD:229478
- Maximum LivingJointAssureTurmeric · Curcumin (Form: from Turmeric) Note: 95% extract100 mgper 2 Capsule(s)DSLD:2927
- MD.LifeStop Restless Legs300 mgper 2 Capsule(s)DSLD:283630
- MediPlan Diet ServicesLipo CapsCurcumin Note: powder6 mgper 1 Capsule(s)DSLD:206844
- Metabolic MaintenanceCurcumin + C 400 mgCurcuminoids · 23% curcuminoids from Curcuma longa root400 mgper 1 Capsule(s)DSLD:274186
- MetagenicsGolden FusionCurcumin · proprietary mix of Curcumin50 mgper 9 Gram(s)DSLD:295716
- MetagenicsPhyto Complete5 mgper 20 Tablet(s)DSLD:27940
- MN Morphogen NutritionOrthogen Cranberry AppleTurmeric500 mgper 9.5 Gram(s)DSLD:260957
- MN Morphogen NutritionOrthogen Pineapple MangoCurcuminoids · 95% curcuminoids500 mgper 9.5 Gram(s)DSLD:260945
- Morphogen NutritionMorphoprimeCurcuminoids · Curcumin (Form: 95% Curcuminoids)500 mgper 6 Capsule(s)DSLD:212817
- Morphogen NutritionOrthogen Juicy OrangeTurmeric · Curcumin (Form: from Turmeric (Form: 95% Curcuminoids) PlantPart: root)500 mgper 9.5 Gram(s)DSLD:212812
- Moss NutritionAntioxidant SelectCurcumin Phytosome25 mgper 2 Capsule(s)DSLD:334909
- Moss NutritionArthroSelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid Complex)75 mgper 4 Capsule(s)DSLD:275495
- Moss NutritionArthroSelectCurcuma longa Rhizome Extract75 mgper 4 Capsule(s)DSLD:329157
- Moss NutritionCurcuSelectCurcuma longa root extract500 mgper 1 Capsule(s)DSLD:306485
- Moss NutritionCV SelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid)50 mgper 2 Capsule(s)DSLD:187437
- Moss NutritionCV SelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid)50 mgper 2 Capsule(s)DSLD:187446
- Moss NutritionGI SelectCurcuma longa Extract · 95% tetrahydrocurcuminoids100 mgper 3.95 Gram(s)DSLD:334929
- Moss NutritionHepatoDetox SelectCurcuma longa root extract · Meriva Curcumin Phytosome (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid Complex)50 mgper 1 Capsule(s)DSLD:334931
- Moss NutritionHomocysteine SelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid)50 mgper 1 Capsule(s)DSLD:247973
- Moss NutritionInflammaSelectCurcuma longa root extract100 mgper 2 Capsule(s)DSLD:329173
- Moss NutritionMotility SelectCurcuma longa root extract50 mgper 3 Capsule(s)DSLD:334942
- Moss NutritionOculoSelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid)50 mgper 2 Capsule(s)DSLD:217756
- Moss NutritionOculoSelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid)50 mgper 2 Capsule(s)DSLD:275542
- Moss NutritionProstate SelectCurcuma longa root extract50 mgper 3 Capsule(s)DSLD:329175
- Moss NutritionSacroSelectCurcuma longa root extract · Meriva Curcumin Phytosome Complex (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, and Phospholipid)250 mgper 41.8 Gram(s)DSLD:191046
- Moss NutritionSacroSelectCurcuma longa root extract · Meriva Curcumin Phytosome (Form: Curcuma longa root extract PlantPart: root Genus: Curcuma Species: longa, & Phospholipid Complex)250 mgper 41.8 Gram(s)DSLD:217734
- MRMVegan Joint Synergy Motion100 mgper 2 Vegan Capsule(s)DSLD:178466
- MRM NutritionJoint Synergy +20 mgper 2 Capsule(s)DSLD:319095
- MTS NutritionMachine MotionCurcumin · std. min. 45% curcuminoids500 mgper 3 Capsule(s)DSLD:323111
- NanoNutraCurcumin250 mgper 6 Milliliter(s)DSLD:252247
- Natural FactorsCurcuminRich TheracurminTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 1 Capsule(s)DSLD:180084
- Natural FactorsLiver Support75 mgper 3 Capsule(s)DSLD:38658
- Natural FactorsMultiFactors Men's75 mgper 3 Capsule(s)DSLD:8355
- Natural FactorsWellBetX Complete Multi12.5 mgper 2 Tablet(s)DSLD:282650
- Natural Factors CurcuminRichCardio CurcumizerTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 1 Softgel(s)DSLD:180140
- Natural Factors CurcuminRichDouble Strength TheracurminTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 1 Capsule(s)DSLD:52839
- Natural Factors CurcuminRichDouble Strength TheracurminTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 1 Capsule(s)DSLD:52843
- Natural Factors CurcuminRichJoint CurcumizerTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 1 Vegetarian Capsule(s)DSLD:180138
- Natural Factors CurcuminRichMemory CurcumizerTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 2 Vegetarian Capsule(s)DSLD:180129
- Natural Factors CurcuminRichMuscle Recovery & Growth CurcumizerTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 5.2 Gram(s)DSLD:220380
- Natural Factors CurcuminRichTheracurminTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 1 Capsule(s)DSLD:180095
- Natural Factors CurcuminRichTheracurminTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 1 Capsule(s)DSLD:52847
- Natural Factors CurcuminRichTheracurmin & L-GlutamineTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric30 mgper 5.2 Gram(s)DSLD:247486
- Natural Factors CurcuminRichTheracurmin Double StrengthTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 1 Vegetarian Capsule(s)DSLD:182994
- Natural Factors CurcuminRichWhole Body CurcumizerTurmeric · Theracurmin Curcumin extract (Form: from Turmeric PlantPart: root Genus: Curcuma Species: longa) Note: A highly bioavailable form of curcumin - the most active curcuminoid in turmeric60 mgper 1 Softgel(s)DSLD:180139
- Natural Factors Three BrainsCurcumin500 mgper 1 Vegetarian Capsule(s)DSLD:282116
- Natural Factors Three BrainsCurcumin500 mgper 1 Vegetarian Capsule(s)DSLD:76059
- Natural Factors WomenSenseGI SenseCurcumin167 mgper 1 Vegetarian Capsule(s)DSLD:179206
- Nature's AnswerAntioxidant SupremeCurcuminoids · Curcumin (Form: 95% Curcuminoids)200 mgper 2 Capsule(s)DSLD:60282
- Nature's Lab GoldTurmeric Extract 1,000 mgTurmeric Rhizome Extract · standardized to 95% curcuminoids1,000 mgper 2 Capsule(s)DSLD:334730
- Nature's WayBroad Spectrum Hemp+ RecoveryTurmeric rhizome Complex · Theracurmin (Form: Enhanced bioavailability Turmeric rhizome Complex (Form: providing 30% Curcumin Note: 90 mg) PlantPart: rhizome)300 mgper 1 Capsule(s)DSLD:213013
- Nature's WayCurica Turmeric 600 mg600 mgper 2 Vegan Capsule(s)DSLD:259371
- Nature's WayCurica Turmeric Drops Orange FlavoredCurcuminoids · Theracurmin (Form: enhanced bioavailability Turmeric rhizome complex PlantPart: rhizome, providing 30% Curcuminoids Note: 90 mg)300 mgper 2 mLDSLD:201110
- Nature's WayRecover PowderTurmeric rhizome Complex · Theracurmin (Form: Enhanced bioavailability Turmeric rhizome Complex (Form: providing 30% Curcumin Note: 90 mg) PlantPart: rhizome)600 mgper 0.5 TbspDSLD:205153
- Nature's WayTurmeric ComplexCurcumin · Theracurmin (Form: enhanced bioavailability water-dispersible Turmeric (Curcuma longa) rhizome Complex PlantPart: rhizome Genus: Curcuma Species: longa, providing 30% Curcumin Note: 30 mg)100 mgper 1 Capsule(s)DSLD:212953
- Natures Plus BrainCeutixOmega+Curcuma longa · Longvida optimized Curcumin extract (Form: from Curcuma longa (Form: standardized to 23% Curcuminoids Note: 46 mg) PlantPart: rhizome Genus: Curcuma Species: longa)200 mgper 2 Softgel(s)DSLD:188885
- Natures Plus HempCeutixReliefCurcuma longa · Longvida Optimized Curcumin extract (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)200 mgper 2 Capsule(s)DSLD:223058
- Nootropics DepotCurcumin + Peperine CapsulesCurcumin Note: 95%1,000 mgper 2 Capsule(s)DSLD:251098
- Nootropics DepotCurcumin + Piperine CapsulesCurcumin Note: 95%1,000 mgper 2 Capsule(s)DSLD:251097
- Nootropics DepotCurcumin 95% Extract500 mgper 0.5 Gram(s)DSLD:232143
- Nootropics DepotLongVida Optimized Curcumin Capsules 400 mgCurcuma longa Rhizome Extract400 mgper 1 Capsule(s)DSLD:285821
- Nootropics DepotLongVida PowderCurcuma longa200 mgper 0.2 Gram(s)DSLD:232357
- Nordic NaturalsOmega CurcuminCurcuma longa400 mgper 2 Softgel(s)DSLD:221657
- Nordic NaturalsOmega Memory with CurcuminCurcuma longa400 mgper 2 Softgel(s)DSLD:223436
- NOWCurcuBrain 400 mgCurcumin · min. 20% curcuminoids400 mgper 1 Veg Capsule(s)DSLD:314125
- NOWCurcumin Phytosome500 mgper 1 Veg Capsule(s)DSLD:314128
- NS Natural StacksLiquid Curcumin With Coconut OilTumeric · Curcumin liquid extract (Form: from Tumeric PlantPart: root)50 mgper 2 Softgel(s)DSLD:66588
- NuMedicaCurcuCalmTurmeric Rhizome Extract · standardized to 95% curcuminoids375 mgper 3 Capsule(s)DSLD:323507
- NuMedicaDIM EstroTurmeric Root Extract · 95% pure curcuminoids600 mgper 2 Capsule(s)DSLD:323526
- NuMedicaGluten Support PacketsTurmeric Root Extract · 95% pure curcuminoids250 mgper 1 Packet(s)DSLD:323539
- NuMedicaPower Greens Premium Natural BerryCurcuminoids · Curcumin extract (Form: 95% Curcuminoids)25 mgper 11.7 Gram(s)DSLD:182976
- NutraBioExtreme Joint CareCurcuma longa extract200 mgper 4 Capsule(s)DSLD:248323
- NutraBio PerformanceExtreme Joint CareCurcumin Phytosome200 mgper 4 Capsule(s)DSLD:322547
- NutraKeyTurmeric Curcumin ComplexCurcuminoids300 mgper 3 Capsule(s)DSLD:287424
- NutrasalOptima C-PCCurcumin · Longvida RD (Form: optimized Curcumin (Form: from Curcuma longa PlantPart: root Genus: Curcuma Species: longa))555 mgper 1 tspDSLD:214090
- Nutri-WestComplete Whey-G Protein Powder25 mgper 1 Scoop(s)DSLD:27680
- NuturaProteo PlusCurcuma longa extract100 mgper 2 Tablet(s)DSLD:239606
- OptiChoiceCogniPro Sport 3.0Curcuminoids · Curcumin (Form: standardized to 95% Curcuminoids)75 mgper 4 Softgel(s)DSLD:216989
- Ormus MineralsNatural Brain Focus Booster95%amount not statedper 2 Capsule(s)DSLD:269150
- OxyLife Nutritional SupplementsPhenocane Curcumin & DLPA250 mgper 1 Capsule(s)DSLD:16975
- Patient One 1 MediNutritionalsEnflamenCurcuma longa · Meriva Phytosome Turmeric Complex (Form: Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa, Glycine max Soybeans Genus: Glycine Species: max, Standardized to 18- 22% Curcuminoids Note: 18-22 mg)100 mgper 3 Capsule(s)DSLD:249255
- PharmaxCurcumin ComplexCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)400 mgper 1 Capsule(s)DSLD:55657
- PharmaxMin-InflammCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)190 mgper 1 Capsule(s)DSLD:55647
- PharmaxMSM ComplexCurcuma longa · Curcumin (Form: from Curcuma longa PlantPart: rhizome Genus: Curcuma Species: longa)15 mgper 1 Capsule(s)DSLD:56158
- Physician's ChoiceTurmericCurcuminoids · 95% Curcuminoids500 mgper 2 Veggie Capsule(s)DSLD:277825
- PhytAge LabsUrgent fungus Destroyer100 mgper 2 Capsule(s)DSLD:276447
- Primal BlueprintPrimal Damage Control50 mgper 1 Capsule(s)DSLD:286796
- Priority One Nutritional SupplementsDiamendTurmeric Rhizome Extract · 18%300 mgper 3 Tablet(s)DSLD:310766
- Priority One Nutritional SupplementsEnflamTurmeric Rhizome Extract · Extract 95%100 mgper 4 Vegetarian Capsule(s)DSLD:277443
- Priority One Nutritional SupplementsUrinary TranquilityTurmeric · ODN 95%100 mgper 3 Vegetarian Capsule(s)DSLD:277426
- ProCapsBreast HealthPhospholipids · turmeric 95% extract40 mgper 2 Capsule(s)DSLD:331519
- ProCapsLiver Anti-Oxidant ExtractsPhospholipids · 95% extract100 mgper 1 Capsule(s)DSLD:331570
- ProCapsMaximum Joint EffortPhospholipids · 95% extract100 mgper 1 Packet(s)DSLD:331577
- ProCapsMemory & Brain with Acetyl L-CarnitinePhospholipids50 mgper 2 Capsule(s)DSLD:331579
- ProCapsSpice of LifePhospholipids · 95%40 mgper 1 Capsule(s)DSLD:331600
- ProCapsTurmeric 400 CurcuminPhospholipids · 95% extract400 mgper 1 Capsule(s)DSLD:331603
- ProCapsUltimate Anti-Oxidant ExtractsPhospholipids · 95% extract100 mgper 2 Capsule(s)DSLD:331605
- ProCapsWomen's Founder'sPhospholipids · turmeric, 95% extract (root) and phospholipids50 mgper 1 Packet(s)DSLD:331636
- ProCaps LaboratoriesLiver Anti-Oxidant ExtractsPhospholipids · 95% extract100 mgper 1 Capsule(s)DSLD:320140
- ProCaps LaboratoriesMemory And Brain with Acetyl L-Carnitine and PC Liver and BrainPhospholipids · Turmeric, 95% extract50 mgper 5 Capsule(s)DSLD:320155
- ProCaps LaboratoriesMen's Elite 200Phospholipids25 mgper 1 Packet(s)DSLD:320162
- ProCaps LaboratoriesMillion ORAC Standardized ExtractsPhospholipids · Curcumin Phospholipid Complex (Form: 95% Turmeric extract PlantPart: root, and Phospholipids)100 mgper 1 Capsule(s)DSLD:275275
- ProCaps LaboratoriesTurmeric & Ginger ExtractsPhospholipids · 95% extract200 mgper 1 Capsule(s)DSLD:320284
- ProCaps LaboratoriesWomen's Elite 200Phospholipids · turmeric, 95% extract (root) and phospholipids25 mgper 1 Packet(s)DSLD:320317
- ProCaps LaboratoriesWomen's Founder'sPhospholipids · turmeric, 95% extract (root) and phospholipids50 mgper 1 Packet(s)DSLD:320318
- ProCaps LaboratoriesWorld HealthPhospholipids · 95% Turmeric extract40 mgper 2 Capsule(s)DSLD:331639
- Progressive Professional from Progressive LaboratoriesBP Natural375 mgper 2 Capsule(s)DSLD:261205
- Progressive Professional from Progressive LaboratoriesHLA Joint SupportTurmeric root extract238 mgper 3 Capsule(s)DSLD:261238
- Protocol For Life BalanceCogumin SLCP 400 mgCurcuma longa400 mgper 1 Veg Capsule(s)DSLD:292257
- Protocol For Life BalanceCurcumin PC with MerivaTurmeric Rhizome Extract/Phosphatidylcholine Complex500 mgper 1 Capsule(s)DSLD:326430
- Pure PrescriptionsRecovery CBDTurmeric Root Extract · standardized greater than or equal to 95% Curcuminoids40 mgper 1 Softgel(s)DSLD:317095
- PureFormulasOptimized CurcuminCurcuma longa · Longvida Optimized Curcumin extract (Form: from Curcuma longa PlantPart: rhizomes Genus: Curcuma Species: longa)400 mgper 2 Vegetarian Capsule(s)DSLD:228499
- PureFormulasPhyto-Xtra with DIM125 mgper 1 Vegetarian Capsule(s)DSLD:205536
- Puritan's PrideCurcumin C3 Reduct Chewables 200 mg Delicious Mixed Berry Flavored200 mgper 2 Chewable Tablet(s)DSLD:286308
- Purity ProductsChris Kilham's Green Tea CRCurcuma longa250 mgper 2 Vegetarian Capsule(s)DSLD:243419
- Purity ProductsChris Kilham's Green Tea CR PhytosomeCurcuma longa250 mgper 2 Vegetarian Capsule(s)DSLD:243420
- Purity ProductsCurcuBriteCurcuma longa extract400 mgper 2 Vegetarian Capsule(s)DSLD:243687
- Purity ProductsPerfect Multi Super EssentialsTurmeric extract5 mgper 3 Capsule(s)DSLD:210018
- Purity ProductsPerfect Multi Super EssentialsTurmeric extract5 mgper 3 Capsule(s)DSLD:244037
- Purity ProductsUltimate CurcuminCurcuma longa extract500 mgper 2 Capsule(s)DSLD:244259
- PuriumJoint-Flexextract300 mgper 3 Capsule(s)DSLD:313760
- QualiaQualia SenolyticCurcuma longa400 mgper 6 Vegetarian Capsule(s)DSLD:320866
- Quality Of LifeCartiquilMeriva Curcumin Phytosome Note: Proprietary Blend of500 mgper 2 Vegetarian Capsule(s)DSLD:175579
- Quantum HealthDigital BlueTurmeric rhizome extract100 mgper 2 Softgel(s)DSLD:299876
- QunolLiquid Turmeric Extra Strength 1000 mg Tropical Orange FlavorCurcuma longa Rhizome Extract · 95% curcuminoids1,000 mgper 15 mLDSLD:321409
- Remedy+The Cap Premium Hemp ExtractCurcumin · standardized 6% total curcuminoids250 mgper 1 Softgel(s)DSLD:314598
- Renue By ScienceResveratrol w/ Curcumin Lipo Gel75 mgper 2 mLDSLD:319026
- Return HealthyITISExtract, 95%202.5 mgper 4 Capsule(s)DSLD:313315
- Ron Teeguarden's Dragon HerbsActivated CurcuminCurcuma longa Extractamount not statedper 0.5 Teaspoon(s)DSLD:279288
- Root2Turmeric Extract Curcumin C3 ComplexTurmeric Rhizome Extract · Standardized to 95% Curcuminoids (1,102 mg)1,160 mgper 2 Capsule(s)DSLD:277446
- Rx VitaminsARTH-9Curcuma longa · Curcumin (Form: standarized Curcuma longa (Form: supplying 90- 95% Curcuminoids) Genus: Curcuma Species: longa)100 mgper 2 Capsule(s)DSLD:42049
- SafrelCurcumin+Turmeric powder500 mgper 1 Capsule(s)DSLD:318396
- Signature SupplementsFibroid CleanzCurcuma longa100 mgper 2 Capsule(s)DSLD:338735
- Signature SupplementsSciatic EaseCurcuma longa100 mgper 2 Capsule(s)DSLD:338936
- Smarter NutritionSmarter CurcuminCurcuma longa · standardized to minimum 95% tetrahydrocurcuminoids400 mgper 2 Vegetarian Softgel(s)DSLD:261373
- SolarayTurmeric Gummies Natural Mango FlavorTurmeric Rhizome Extract260 mgper 2 Gummy(ies)DSLD:326139
- SolgarFull Spectrum Curcuminfull spectrum Curcumin liquid extract Note: providing:amount not statedper 1 Liquid Extract Softgel(s)DSLD:204502
- SolgarFull Spectrum Curcuminfull spectrum Curcumin liquid extract Note: providing:amount not statedper 1 Softgel(s)DSLD:219376
- SolgarFull Spectrum Curcuminfull spectrum Curcumin liquid extract Note: providing:amount not statedper 1 Liquid Extract Softgel(s)DSLD:241090
- SolgarFull Spectrum Curcumin Brain WorksFull Spectrum Curcumin Note: providingamount not statedper 2 Softgel(s)DSLD:222792
- SolgarFull Spectrum Curcumin Brain WorksFull Spectrum Curcumin Note: providingamount not statedper 3 Capsule(s)DSLD:242475
- SolgarFull Spectrum Curcumin Sleep EaseFull Spectrum Curcumin Note: providingamount not statedper 1 Softgel(s)DSLD:222791
- SolgarFull Spectrum Curcumin Sleep EaseFull Spectrum Curcumin Note: providingamount not statedper 2 Capsule(s)DSLD:242477
- Source NaturalsTheracurmin 300 mgTurmeric rhizome [Curcuma longa] ext. · Theracurmin (Form: micronized, water-dispersible Turmeric rhizome [Curcuma longa] ext. PlantPart: rhizome Genus: Curcuma Species: longa Note: yielding)300 mgper 1 Vegetarian Capsule(s)DSLD:78331
- Source NaturalsTheracurmin 300 mgTurmeric rhizome [Curcuma longa] extract · Theracurmin (Form: micronized, water-dispersible Turmeric rhizome [Curcuma longa] extract PlantPart: rhizome Genus: Curcuma Species: longa Note: yielding)300 mgper 1 Vegetarian Capsule(s)DSLD:78336
- Source NaturalsTheracurmin 600 mgTurmeric rhizome [Curcuma longa] extract · Theracurmin (Form: micronized, water-dispersible Turmeric rhizome [Curcuma longa] extract PlantPart: rhizome Genus: Curcuma Species: longa Note: yielding)600 mgper 1 Vegetarian Capsule(s)DSLD:274050
- Source NaturalsTheracurmin 600 mgTurmeric rhizome [Curcuma longa] ext. · Theracurmin (Form: micronized, water-dispersible Turmeric rhizome [Curcuma longa] ext. PlantPart: rhizome Genus: Curcuma Species: longa Note: yielding)600 mgper 1 Vegetarian Capsule(s)DSLD:78344
- Sports ResearchTurmeric Curcumin 500 mgTurmeric Rhizome Extract500 mgper 1 Softgel(s)DSLD:326288
- Sports ResearchTurmeric Curcumin C3 ComplexTurmeric Rhizome Extract500 mgper 1 Softgel(s)DSLD:317006
- SunwarriorJoint Health Formula 1200 mg Chocolate Mint FlavorCurcuminoids · 95% Curcuminoids20 mgper 1 mLDSLD:317832
- SuperSmartNatural RapalogsCurcuma longa · extracted from curcuma longa500 mgper 1 Capsule(s)DSLD:332463
- SuperSmartRehabCurcuma longa Extract · 95% curcumin50 mgper 2 Capsule(s)DSLD:332491
- Supplement SpotResvert Plus50 mgper 2 Capsule(s)DSLD:264651
- SwansonMobility EssentialsCurcumin Note: rhizome50 mgper 3 Veggie Capsule(s)DSLD:203293
- Systemic FormulasMoRS LQ Methylation Donoramount not statedper 0.5 Dropper(s)DSLD:22469
- The Cheat System DietNutritional Detox PacketsCurcuma longa extract200 mgper 6 Capsule(s)DSLD:37484
- The Cheat System DietNutritional Detox Packets200 mgper 6 Capsule(s)DSLD:64330
- The Vitamin ShoppeUltimate Gold Fast Acting Joint Care150 mgper 2 Tablet(s)DSLD:55795
- ThorneA.M.Curcumin Phytosome200 mgper 3 Capsule(s)DSLD:328833
- ThorneA.M.Curcumin Phytosome200 mgper 3 Capsule(s)DSLD:336315
- ThorneCurcumin Phytosome 1000 mgCurcuma longa Root Extract1 Gram(s)per 1 Capsule(s)DSLD:284239
- ThorneCurcumin Phytosome 1000 mgCurcuma longa Root Extract1 Gram(s)per 1 Capsule(s)DSLD:298077
- ThorneCurcumin Phytosome 1000 mgCurcumin Phytosome Complex1 Gram(s)per 1 Capsule(s)DSLD:298078
- ThorneCurcumin Phytosome 1000 mgCurcumin Phytosome1 Gram(s)per 1 Capsule(s)DSLD:328825
- ThorneCurcumin Phytosome 1000 mgCurcumin Phytosome · This product uses Indena S.p.A's curcumin phytosome (Meriva). Meriva is a registered trademark of Indena S.p.A.1 Gram(s)per 1 Capsule(s)DSLD:328826
- ThorneCurcumin Phytosome 500 mgCurcumin Phytosome500 mgper 1 Capsule(s)DSLD:337856
- ThorneEnteroMend Orange Vanilla FlavoredCurcumin Phytosome250 mgper 5.6 Gram(s)DSLD:337859
- ThorneJoint Support Nutrients250 mgper 4 Capsule(s)DSLD:284229
- ThorneMediClear-SGS Chocolate FlavoredCurcumin Phytosome400 mgper 51.6 Gram(s)DSLD:327306
- ThorneMediClear-SGS Vanilla FlavoredCurcumin Phytosome400 mgper 46.6 Gram(s)DSLD:323084
- ThorneMetabolic HealthCurcumin Phytosome · This product uses Indena S.pA's curcumine phytomsome (Meriva) and Bergamot phytosome (Vazguard).250 mgper 2 Capsule(s)DSLD:298079
- ThorneMetabolic HealthCurcumin Phytosome250 mgper 2 Capsule(s)DSLD:336322
- ThorneMulti-Vitamin Elite A.M.Curcuma longa Root Extract200 mgper 3 Capsule(s)DSLD:321975
- ThornePolyResveratrol-SRCurcuma longa extract100 mgper 2 Capsule(s)DSLD:284255
- ThornePolyResveratrol-SRCurcuma longa extract100 mgper 2 Capsule(s)DSLD:336336
- ThorneSynaQuellCurcumin Phytosome125 mgper 7.8 Gram(s)DSLD:337875
- Totally ProductsSuper Fat Burner Extreme25 mgper 4 Capsule(s)DSLD:294259
- Totally ProductsTurmeric and Ginger Gummies 270 mgTurmeric Rhizome Extract · Standardized for 95% Curcuminoids260 mgper 2 Gummy(ies)DSLD:294246
- Traditional NutritionalsCMO PlusCurcumin Note: 95% pure50 mgper 2 Capsule(s)DSLD:11461
- Traditional NutritionalsProsta-Plex Plus100 mgper 4 Capsule(s)DSLD:11465
- USANAHepasil DTXCurcuma longa L.4 mgper 3 Tablet(s)DSLD:322318
- ViMultiSweatFX13 mgper 2 Capsule(s)DSLD:231029
- Vital NutrientsBCQCurcuma longa Rhizome Extract · standardized to 85% total curcuminoids600 mgper 1 Vegetarian Capsule(s)DSLD:304947
- Vital NutrientsCurcumin Extract 500 mgCurcuma longa Rhizome Extract · standardized to 8% total curcuminoids1,000 mgper 2 Vegetarian Capsule(s)DSLD:304972
- Vital NutrientsCurcumin Extract 700 mgCurcuma longa Rhizome Extract · standardized to 8% total curcuminoids1,400 mgper 2 Vegetarian Capsule(s)DSLD:304973
- Vital NutrientsDetox FormulaCurcuma longa Rhizome Extract · 85% Total curcuminoids100 mgper 2 Vegetarian Capsule(s)DSLD:304974
- Vital NutrientsHormone BalanceCurcuma longa Rhizome Extract · 85% Total curcumioids100 mgper 1 Vegetarian Capsule(s)DSLD:305053
- Vital NutrientsJoint Ease 2.0Curcuma longa Rhizome Extract487 mgper 3 Vegetarian Capsule(s)DSLD:305058
- Vital NutrientsLiver SupportCurcuma longa · standardized to 85-90% total curcuminoids200 mgper 2 Capsule(s)DSLD:305084
- Vital NutrientsLiver Support IICurcuma longa L. Rhizome Extract · standardized to 85% total curcuminoids300 mgper 1 Vegetarian Capsule(s)DSLD:305085
- Vital NutrientsPhyto-Curcumin plus EnzymesCurcuma longa Rhizome Extract · standardized to 18%-22% total curcuminoids.1,275 mgper 1 Vegetarian Capsule(s)DSLD:305138
- Vital NutrientsVital ClearCurcuminoids · Curcumin rhizome extract (Form: 85- 90% Curcuminoids) PlantPart: rhizome200 mgper 47 Gram(s)DSLD:208148
- Vital NutrientsVital ClearCurcuminoids · Curcumin rhizome extract (Form: 85- 90% Curcuminoids) PlantPart: rhizome200 mgper 47 Gram(s)DSLD:223160
- VitanicaMid-Life SymmetryCurcuma longa Root Extract50 mgper 1 Capsule(s)DSLD:302797
- WeCare NaturallyJoint SupportCurcuma longa extract250 mgper 4 Capsule(s)DSLD:65081
- WeCare NaturallySuper Detox50 mgper 2 Capsule(s)DSLD:65120
- Whitaker NutritionMind & Memory EssentialsCurcuma longa Rhizome Extract400 mgper 1 Capsule(s)DSLD:322305
- Whitaker NutritionTriComfort EssentialsSunflower Lecithin200 mgper 1 Capsule(s)DSLD:230601
- Whitaker NutritionTriComfort GoldSunflower Lecithinamount not statedper 1 Capsule(s)DSLD:230602
- Whitaker NutritionTriveratrol GoldSunflower Lecithin500 mgper 2 Capsule(s)DSLD:230604
- Whitaker NutritionTriveratrol Plus200 mgper 2 Capsule(s)DSLD:201654
- Williams NutritionJoint Advantage Gold 5X TurmericSunflower Lecithin500 mgper 3 Tablet(s)DSLD:287845
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:260748
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:260602
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:261199
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:262436
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:262437
- Wonder LaboratoriesCurcumin 950 mg950 mgper 2 Capsule(s)DSLD:262438
- Wonder LaboratoriesCurcurmin 950 mg950 mgper 2 Capsule(s)DSLD:260601
- Wonder LabsCurcumin 950 mg with BioPerineCurcumin Note: from950 mgper 2 Capsule(s)DSLD:260749
- Wonder LabsCurcumin 950 mg with BioPerineCurcumin Note: from950 mgper 2 Capsule(s)DSLD:260751
- Wonder LabsTurmax475 mgper 1 Capsule(s)DSLD:262216
- Wonder LabsTurmax475 mgper 1 Capsule(s)DSLD:262414
- XYMOGENOptiCleanse GHI Chocolate Mint200 mgper 64 Gram(s)DSLD:6576
- XYMOGENOptiCleanse GHI Rice Original200 mgper 49 Gram(s)DSLD:6566
- XYMOGENOptiCleanse GHI Rice Raspberry Lemonade200 mgper 60 Gram(s)DSLD:6567
- XYMOGENOptiCleanse GHI Rice Vanilla Delight200 mgper 60 Gram(s)DSLD:6574
- ZenMenSciatic Nerve Support95%500 mgper 2 Veggie Capsule(s)DSLD:279113
- Zenwise HealthJoint SupportCurcuma longa · Curcumin (Form: from Curcuma longa Genus: Curcuma Species: longa)100 mgper 3 Tablet(s)DSLD:229219
- Zenwise LabsJoint Support100 mgper 3 Tablet(s)DSLD:267979
Label record: NIH Office of Dietary Supplements · CC0
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- curcumin
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
205 trials
205 registered trials without posted results · Overdue (FDAAA 801): 109 · Showing 120 of 205
109 past the window11 within it, or no actual date
- NCT05377242completed2026-06-22a university or hospital
- NCT07785986completed2026-05-23a university or hospital
- NCT07184268completed2026-03-15a university or hospital
- NCT03431896completed2026-03-09a university or hospital
- NCT07089329completed2026-02-25a university or hospital
- NCT05816707completed2026-02-01a university or hospital
- NCT07523256completed2026-01-31a university or hospital
- NCT06886035completed2025-12-31a university or hospital
- NCT07052890completed2025-12-08a university or hospital
- NCT06974058completed2025-11-18a university or hospital
- NCT04705220completed2025-10-16industry
- NCT06342830completed2025-09-20a university or hospitalpast the reporting window
Show the remaining 193
- NCT07349264completed2025-07-31industrypast the reporting window
- NCT07278128completed2025-07-14a university or hospitalpast the reporting window
- NCT07149961completed2025-04-25a university or hospitalpast the reporting window
- NCT04431700terminated— Unable to complete enrollment2025-03-31a university or hospitalpast the reporting window
- NCT06653231completed2025-02-01a university or hospitalpast the reporting window
- NCT06763809completed2024-12-12industrypast the reporting window
- NCT05062486completed2024-11-07a university or hospitalpast the reporting window
- NCT06690814completed2024-11-01a university or hospitalpast the reporting window
- NCT06029023completed2024-09-30a university or hospitalpast the reporting window
- NCT06867939completed2024-09-20a university or hospitalpast the reporting window
- NCT06458465completed2024-09-01a university or hospitalpast the reporting window
- NCT06097871completed2024-07-24industrypast the reporting window
- NCT07585825completed2024-06-21industrypast the reporting window
- NCT06177483completed2024-04-05industrypast the reporting window
- NCT05472753completed2024-02-27a university or hospitalpast the reporting window
- NCT06984640completed2024-02-14a university or hospitalpast the reporting window
- NCT07078630completed2024-01-24a university or hospitalpast the reporting window
- NCT06124326completed2024-01-20industrypast the reporting window
- NCT05753436completed2024-01-01a university or hospitalpast the reporting window
- NCT06044142completed2023-12-30a university or hospitalpast the reporting window
- NCT04413266completed2023-10-05a university or hospitalpast the reporting window
- NCT05714670completed2023-10-01a university or hospitalpast the reporting window
- NCT05414838completed2023-09-26a university or hospitalpast the reporting window
- NCT06281353completed2023-09-06a university or hospitalpast the reporting window
- NCT05147376completed2023-08-07a university or hospitalpast the reporting window
- NCT06605911completed2023-08-01a university or hospitalpast the reporting window
- NCT04007224completed2023-06-28a university or hospitalpast the reporting window
- NCT05332743completed2023-06-08industrypast the reporting window
- NCT04590196completed2023-06-01a university or hospitalpast the reporting window
- NCT05775237completed2023-06-01a university or hospitalpast the reporting window
- NCT05206266completed2023-05-30a university or hospitalpast the reporting window
- NCT04998617completed2023-05-05a university or hospitalpast the reporting window
- NCT05542394completed2023-04-06a university or hospitalpast the reporting window
- NCT06268483completed2023-03-28a university or hospitalpast the reporting window
- NCT05982197completed2023-03-01a university or hospitalpast the reporting window
- NCT05761327completed2023-02-18a university or hospitalpast the reporting window
- NCT05037162completed2023-01-21industrypast the reporting window
- NCT05045443completed2022-12-31a university or hospitalpast the reporting window
- NCT04654689completed2022-11-12a university or hospitalpast the reporting window
- NCT03670875completed2022-10-31a government bodypast the reporting window
- NCT04661267completed2022-10-31industrypast the reporting window
- NCT05520424completed2022-10-30industrypast the reporting window
- NCT04784234terminated— company was bought and discontinued producing supplement2022-10-27a university or hospitalpast the reporting window
- NCT05535231completed2022-10-03industrypast the reporting window
- NCT04879810completed2022-08-02a university or hospitalpast the reporting window
- NCT05518019completed2022-06-29industrypast the reporting window
- NCT06300021completed2022-05-20industrypast the reporting window
- NCT06187298completed2022-05-16a university or hospitalpast the reporting window
- NCT04912921completed2022-05-15a university or hospitalpast the reporting window
- NCT03953261terminated— COVID and lack of support staff 2. lack of support staff to conduct the study2022-04-13a university or hospitalpast the reporting window
- NCT05016596completed2022-04-11a university or hospitalpast the reporting window
- NCT03980509completed2022-03-24a university or hospitalpast the reporting window
- NCT04603690completed2022-01-31a university or hospitalpast the reporting window
- NCT05430087completed2022-01-31a university or hospitalpast the reporting window
- NCT05130671completed2021-12-31a university or hospitalpast the reporting window
- NCT04528212completed2021-11-30a university or hospitalpast the reporting window
- NCT06553144completed2021-11-01a university or hospitalpast the reporting window
- NCT04844658completed2021-10-29industrypast the reporting window
- NCT04744545completed2021-09-30industrypast the reporting window
- NCT05089318completed2021-09-01industrypast the reporting window
- NCT03192059completed2021-06-30a university or hospitalpast the reporting window
- NCT04765527completed2021-06-15a university or hospitalpast the reporting window
- NCT04315350terminated— We stopped recruiting having 8 in each intervention group instead of 9 due to recruitment problems due to COVID19 pandemic2021-06-07a university or hospitalpast the reporting window
- NCT05667376completed2021-05-30a university or hospitalpast the reporting window
- NCT05242718completed2021-05-01industrypast the reporting window
- NCT03475017completed2021-04-29a university or hospitalpast the reporting window
- NCT04972045completed2021-04-23a university or hospitalpast the reporting window
- NCT04208334completed2021-02-24a university or hospitalpast the reporting window
- NCT03864783completed2020-12-16a university or hospitalpast the reporting window
- NCT04421716completed2020-11-30a university or hospitalpast the reporting window
- NCT03542240completed2020-11-13a university or hospitalpast the reporting window
- NCT04281758completed2020-10-01industrypast the reporting window
- NCT04500210completed2020-09-07a university or hospitalpast the reporting window
- NCT04012424completed2020-08-01a university or hospitalpast the reporting window
- NCT04149639completed2020-07-07industrypast the reporting window
- NCT04849182completed2020-06-30a university or hospitalpast the reporting window
- NCT03122613terminated— Decision made by team of investigators2020-05-22a university or hospitalpast the reporting window
- NCT04183556completed2020-04-23a government bodypast the reporting window
- NCT04119752completed2020-04-05a university or hospitalpast the reporting window
- NCT04723849completed2020-03-31a university or hospitalpast the reporting window
- NCT05306002completed2020-03-22a government bodypast the reporting window
- NCT02724202terminated— PI-Initiated study; PI requested closure2020-01-10a university or hospitalpast the reporting window
- NCT03568513completed2020-01-02a university or hospitalpast the reporting window
- NCT04028739completed2019-11-29industrypast the reporting window
- NCT04378972completed2019-11-16a university or hospitalpast the reporting window
- NCT04465851completed2019-11-11a university or hospitalpast the reporting window
- NCT02369549completed2019-11a university or hospitalpast the reporting window
- NCT03289832completed2019-10-23a university or hospitalpast the reporting window
- NCT03483376completed2019-09-30a university or hospitalpast the reporting window
- NCT04107987completed2019-08-31a university or hospitalpast the reporting window
- NCT03795792completed2019-08-06a government bodypast the reporting window
- NCT02439385completed2019-08-01a university or hospitalpast the reporting window
- NCT04439981completed2019-07-08a university or hospitalpast the reporting window
- NCT03290417completed2019-06-20a university or hospitalpast the reporting window
- NCT04890704completed2019-03-31a government bodypast the reporting window
- NCT03746158completed2019-03-01a university or hospitalpast the reporting window
- NCT03769857completed2019-02-20industrypast the reporting window
- NCT04385979completed2019-01-01a university or hospitalpast the reporting window
- NCT03482401completed2018-12-01a government bodypast the reporting window
- NCT03072992completed2018-11-20a university or hospitalpast the reporting window
- NCT03493997completed2018-10-31a university or hospitalpast the reporting window
- NCT03621865completed2018-10-26industrypast the reporting window
- NCT03530787completed2018-10-12a university or hospitalpast the reporting window
- NCT03598205completed2018-09-28a university or hospitalpast the reporting window
- NCT02598726completed2018-09-19a university or hospitalpast the reporting window
- NCT03175757completed2018-08-10industrypast the reporting window
- NCT03530436completed2018-08-10a university or hospitalpast the reporting window
- NCT04032132completed2018-05-06a university or hospitalpast the reporting window
Papers screened
4,676 papers
- Compound
- curcumin
- Screened
- 4,676
- Admitted
- 60
- Discarded
- 2,707
- Not read
- 1,909
- Showing
- 200 of 4,676
Produced a finding60 papers
and 60 more.
Read and discarded2,707 papers
- PMID:17576417cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:17693697cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:18089954cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:18650835cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:19016784cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:19277912cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:19671869cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:20236818cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:21323606cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:21376230cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:7578935cited by PMID:21642934; not about the subject it would be filed under2026-10-13
- PMID:8203375cited by PMID:21642934; not about the subject it would be filed under2026-10-13
and 2,695 more.
Not read yet1,909 papers
and 1,909 more.
Measured, not recorded
- Compound
- curcumin
- Endpoints measured
- 3,692 endpoints
- Recorded as a finding
- No
Show what was measured
broad pharmacological activity spectrum of curcumin (antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, anticancer)
Curcumin has been shown to exhibit antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer activities and thus has a potential against various malignant diseases, diabetes, allergies, arthritis, Alzheimer's disease, and other chronic illnesses.
PMID:17569205 · one of two readings recorded this
reversal of multidrug resistance (MDR) / chemosensitization in cancer cell lines
This overview presents curcumin as a significant chemosensitizer in cancer chemotherapy.
PMID:17569216 · one of two readings recorded this
immunomodulatory effects on lymphoid cell populations, antigen presentation, humoral and cell-mediated immunity, and cytokine production
This review discusses current knowledge on the immunomodulatory effects of curcumin on various facets of the immune response, including its effect on lymphoid cell populations, antigen presentation, humoral and cell-mediated immunity, and cytokine production.
PMID:17569218 · one of two readings recorded this
triacylglycerols
no effect
Consumption of either dose of curcumin did not significantly affect triacylglycerols, or total, LDL, and HDL cholesterol over 1 month or 6 months.
PMID:17951067 · one of two readings recorded this
correlation between plasma curcumin concentration and serum cholesterol
increases
However, the concentrations of plasma curcumin and serum cholesterol were positively and significantly correlated.
PMID:17951067 · one of two readings recorded this
plasma curcumin concentration, HPLC
mean of 490 nmol/L
Not recorded as a finding: no outcome node for circulating curcumin/curcuminoid concentration
The plasma curcumin concentration reached a mean of 490 nmol/L.
PMID:17951067 · one of two readings recorded this
serum triacylglycerols, total cholesterol, LDL cholesterol, HDL cholesterol
no effect
Not recorded as a finding: the result compares a group with itself, not with a control
Consumption of either dose of curcumin did not significantly affect triacylglycerols, or total, LDL, and HDL cholesterol over 1 month or 6 months.
PMID:17951067 · one of two readings recorded this
total, LDL and HDL cholesterol
no effect
Consumption of either dose of curcumin did not significantly affect triacylglycerols, or total, LDL, and HDL cholesterol over 1 month or 6 months.
PMID:17951067 · one of two readings recorded this
triacylglycerols, total cholesterol, LDL cholesterol, HDL cholesterol
no effect
Consumption of either dose of curcumin did not significantly affect triacylglycerols, or total, LDL, and HDL cholesterol over 1 month or 6 months.
PMID:17951067 · one of two readings recorded this
safety of oral curcumin at high dose in Phase I clinical trials
no effect, safe even at 12 g/day
Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailability.
PMID:17999464 · one of two readings recorded this
malondialdehyde
decreases
Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha.
PMID:18588355 · one of two readings recorded this
composite of the above markers in the placebo arm
no effect
No significant improvements were obtained in patients administered placebo.
PMID:18588355 · one of two readings recorded this
endothelial function by digital volume plethysmography with a salbutamol challenge test (reflective index)
decreases, NCB-02: -2.69 +/- 3.02% (baseline) vs -8.19 +/- 5.73% (post-treatment)
Not recorded as a finding: this platform holds no node for the endpoint
Compared with baseline, there was a significant improvement in endothelial function after treatment with atorvastatin (mean +/- SD: -3.63 +/- 3.17% vs -8.95 +/- 6.80%, respectively) and NCB-02 (-2.69 +/- 3.02% vs -8.19 +/- 5.73%, respectively).
PMID:18588355 · one of two readings recorded this
endothelial function, digital volume plethysmography reflective index change after salbutamol challenge
increases, NCB-02 mean change -2.69 +/- 3.02% to -8.19 +/- 5.73%
Not recorded as a finding: this platform holds no node for the endpoint
Compared with baseline, there was a significant improvement in endothelial function after treatment with atorvastatin (mean +/- SD: -3.63 +/- 3.17% vs -8.95 +/- 6.80%, respectively) and NCB-02 (-2.69 +/- 3.02% vs -8.19 +/- 5.73%, respectively).
PMID:18588355 · one of two readings recorded this
endothelial function, digital volume plethysmography reflective index (salbutamol challenge)
increases, NCB-02 mean change -2.69 +/- 3.02% to -8.19 +/- 5.73%
Compared with baseline, there was a significant improvement in endothelial function after treatment with atorvastatin (mean +/- SD: -3.63 +/- 3.17% vs -8.95 +/- 6.80%, respectively) and NCB-02 (-2.69 +/- 3.02% vs -8.19 +/- 5.73%, respectively).
PMID:18588355 · one of two readings recorded this
endothelial function (reflective index, digital volume plethysmography, salbutamol challenge)
decreases, NCB-02: -2.69 +/- 3.02% vs -8.19 +/- 5.73%
Compared with baseline, there was a significant improvement in endothelial function after treatment with atorvastatin (mean +/- SD: -3.63 +/- 3.17% vs -8.95 +/- 6.80%, respectively) and NCB-02 (-2.69 +/- 3.02% vs -8.19 +/- 5.73%, respectively).
PMID:18588355 · one of two readings recorded this
endothelin-1 (ET-1)
decreases
Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha.
PMID:18588355 · one of two readings recorded this
interleukin-6 (IL-6)
decreases
Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha.
PMID:18588355 · one of two readings recorded this
malondialdehyde, endothelin-1, interleukin-6, tumour necrosis factor-alpha
decreases, significant reductions in atorvastatin and NCB-02 groups; no significant improvement with placebo
Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha.
PMID:18588355 · one of two readings recorded this
tumour necrosis factor-alpha (TNFalpha)
decreases
Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha.
PMID:18588355 · one of two readings recorded this
HDL cholesterol
increases
For HDL cholesterol level, there was also a trend that the lower the dose of curcumin, the higher the effect of increase in HDL cholesterol level.
PMID:19151449 · both readings recorded this
LDL cholesterol
decreases
The effects of curcumin on total cholesterol level and LDL cholesterol level, there was a trend that the lower the dose of curcumin, the higher the effect of reduction.
PMID:19151449 · one of two readings recorded this
triglyceride
increases
For triglyceride the pattern was not the same, and the group of moderate-dose curcumin shoed the minimal effect of increase, followed by the low-dose curcumin and finally the high-dose curcumin that showed the highest effect of increase.
PMID:19151449 · one of two readings recorded this
serum total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels
decreases, trend of greater reduction in total and LDL cholesterol with lower curcumin dose
Not recorded as a finding: the comparison was against another active treatment
The effects of curcumin on total cholesterol level and LDL cholesterol level, there was a trend that the lower the dose of curcumin, the higher the effect of reduction.
PMID:19151449 · one of two readings recorded this
total cholesterol and LDL cholesterol
decreases, trend of greater reduction with lower dose
The effects of curcumin on total cholesterol level and LDL cholesterol level, there was a trend that the lower the dose of curcumin, the higher the effect of reduction.
PMID:19151449 · one of two readings recorded this
total cholesterol
decreases
The effects of curcumin on total cholesterol level and LDL cholesterol level, there was a trend that the lower the dose of curcumin, the higher the effect of reduction.
PMID:19151449 · one of two readings recorded this
inducible PGE2 production in blood
decreases, n = 15
It was found that a daily dose of 3.6 g curcumin caused 62% decreases in inducible PGE2 production in blood samples, indicating the biological activity in humans.
PMID:20345353 · one of two readings recorded this
tumour response, advanced pancreatic cancer
n = 21
In this study, out of 21 cases, two patients showed clinical evidence for biological activity after curcumin treatment.
PMID:20345353 · one of two readings recorded this
blood glucose and glycosylated haemoglobin (db/db mice)
decreases
Curcumin lowered the blood glucose and glycosylated hemoglobin levels and suppressed body weight loss in db/db mice.
PMID:20420526 · one of two readings recorded this
cardiac autonomic imbalance (sympathovagal ratio, high-fat-fed rats)
decreases
curcumin supplementation ameliorated cardiac autonomic imbalance in high-fat-fed rats by decreasing the plasma FFA concentration.
PMID:20420526 · one of two readings recorded this
HDL-cholesterol
increases, n = 8
Administration of 10 mg curcumin per day for 30 days to eight human subjects increased HDL-cholesterol, decreased LDL-cholesterol, and increased APO A but decreased APO B and APO A/B.
PMID:20420526 · one of two readings recorded this
LDL-cholesterol
decreases, n = 8
Administration of 10 mg curcumin per day for 30 days to eight human subjects increased HDL-cholesterol, decreased LDL-cholesterol, and increased APO A but decreased APO B and APO A/B.
PMID:20420526 · one of two readings recorded this
plasma fibrinogen
decreases, n = 30
Curcumin significantly lowered the levels of plasma fibrinogen in both men and women.
PMID:20420526 · one of two readings recorded this
plasma curcuminoid absorption (curcumin, demethoxycurcumin, bisdemethoxycurcumin), LC-MS/HPLC
increases, about 29-fold higher absorption for Meriva than for the unformulated curcuminoid mixture
Not recorded as a finding: the comparison was against another active treatment
Total curcuminoid absorption was about 29-fold higher for Meriva than for its corresponding unformulated curcuminoid mixture.
PMID:21413691 · one of two readings recorded this
plasma curcuminoid concentrations (curcumin, demethoxycurcumin, bisdemethoxycurcumin)
increases
Remarkably, phospholipid formulation increased the absorption of demethoxylated curcuminoids much more than that of curcumin (1a), with significant differences in plasma curcuminoid profile between Meriva and its corresponding unformulated curcuminoid mixture.
PMID:21413691 · one of two readings recorded this
plasma curcuminoid (curcumin, demethoxycurcumin, bisdemethoxycurcumin) absorption/AUC
increases, about 29-fold higher absorption for Meriva
Total curcuminoid absorption was about 29-fold higher for Meriva than for its corresponding unformulated curcuminoid mixture.
PMID:21413691 · one of two readings recorded this
catalase activity
decreases, significantly reduced in curcumin group
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · both readings recorded this
glutathione peroxidase activity
decreases, significantly reduced in curcumin group, p = 0.006
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · both readings recorded this
superoxide dismutase activity
decreases, significantly reduced in curcumin group, p = 0.02
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · both readings recorded this
Dermatology Life Quality Index (DLQI)
decreases
As for the QoL, although DLQI scores decreased in both groups (P<0·001 and P=0·003 in the curcumin and placebo groups, respectively), the magnitude of reduction was significantly greater in the curcumin group (P<0·001).
PMID:22099425 · both readings recorded this
pruritus score, visual analogue scale (VAS), SCORAD index
decreases, significant reductions in curcumin group
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
pruritus score
decreases
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
pruritus severity (pruritus score, VAS, SCORAD index, DLQI first question)
decreases, significant reductions in the curcumin group
Not recorded as a finding: no outcome node for pruritus-specific instruments (the vas-pain node is defined for pain, not pruritus)
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
pruritus severity (pruritus score, VAS, SCORAD)
decreases
Not recorded as a finding: vas-pain requires pain intensity; this trial scores pruritus (itch) severity, a different construct, and no node exists for the pruritus score or SCORAD index
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
SCORAD index (overall and objective)
decreases
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
serum substance P concentration
decreases
Not recorded as a finding: no outcome node exists for substance P
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · one of two readings recorded this
serum substance P
decreases, significantly reduced in the curcumin group
Not recorded as a finding: no outcome node for substance P
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · one of two readings recorded this
substance P
decreases, significantly reduced in curcumin group
Serum concentrations of substance P (P<0·001) as well as activities of superoxide dismutase (P=0·02), glutathione peroxidase (P=0·006) and catalase (P<0·001) were significantly reduced in the curcumin group, while no significant change was observed in the placebo group.
PMID:22099425 · both readings recorded this
VAS pruritus score
decreases
Curcumin supplementation was also associated with significant reductions in measures of pruritus severity including the pruritus score (P<0·001), VAS score (P<0·001), overall (P<0·001) and objective SCORAD (P=0·009), and DLQI's first question (P<0·001).
PMID:22099425 · one of two readings recorded this
ACR20/50/70 response
increases
Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group.
PMID:22407780 · one of two readings recorded this
adverse events
no effect
More importantly, curcumin treatment was found to be safe and did not relate with any adverse events.
PMID:22407780 · one of two readings recorded this
American College of Rheumatology (ACR) 20/50/70 response criteria
increases, curcumin group showed highest percentage improvement
Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group.
PMID:22407780 · one of two readings recorded this
Disease Activity Score 28 (DAS28) reduction and ACR20/50/70 response criteria in active rheumatoid arthritis
decreases
Not recorded as a finding: the comparison was against another active treatment
Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group.
PMID:22407780 · one of two readings recorded this
Disease Activity Score 28 (DAS28)
increases, curcumin group showed highest percentage improvement, significantly better than diclofenac sodium group
Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group.
PMID:22407780 · both readings recorded this
Disease Activity Score (DAS28) and ACR response criteria in rheumatoid arthritis
increases, curcumin group showed greater improvement in DAS and ACR scores than the diclofenac sodium group
Not recorded as a finding: the comparison was against another active treatment
Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group.
PMID:22407780 · one of two readings recorded this
aortic augmentation index (AIx), heart-rate corrected
decreases
Heart rate (HR) corrected aortic AIx significantly decreases only in the combined-treatment group.
PMID:22421908 · one of two readings recorded this
aortic systolic blood pressure (tonometry-derived)
decreases
After the interventions, brachial systolic BP (SBP) significantly decreased in both exercise-trained groups (P < 0.05 for both), whereas aortic SBP significantly decreased only in the combined-treatment (e.g., exercise and curcumin) group (P < 0.05).
PMID:22421908 · one of two readings recorded this
aortic systolic blood pressure
decreases, significantly decreased only in the combined exercise-plus-curcumin group
After the interventions, brachial systolic BP (SBP) significantly decreased in both exercise-trained groups (P < 0.05 for both), whereas aortic SBP significantly decreased only in the combined-treatment (e.g., exercise and curcumin) group (P < 0.05).
PMID:22421908 · one of two readings recorded this
brachial systolic blood pressure (tonometry-derived)
decreases
After the interventions, brachial systolic BP (SBP) significantly decreased in both exercise-trained groups (P < 0.05 for both), whereas aortic SBP significantly decreased only in the combined-treatment (e.g., exercise and curcumin) group (P < 0.05).
PMID:22421908 · one of two readings recorded this
brachial systolic blood pressure
decreases, significantly decreased in both exercise-trained groups
After the interventions, brachial systolic BP (SBP) significantly decreased in both exercise-trained groups (P < 0.05 for both), whereas aortic SBP significantly decreased only in the combined-treatment (e.g., exercise and curcumin) group (P < 0.05).
PMID:22421908 · one of two readings recorded this
heart-rate-corrected aortic augmentation index (AIx) by radial applanation tonometry pulse wave analysis
decreases
Not recorded as a finding: the intervention held more than the compound
Heart rate (HR) corrected aortic AIx significantly decreases only in the combined-treatment group.
PMID:22421908 · one of two readings recorded this
heart-rate-corrected aortic augmentation index (AIx), pulse wave analysis by applanation tonometry
decreases, significant decrease only in the combined exercise-plus-curcumin group
Not recorded as a finding: the result compares a group with itself, not with a control
Heart rate (HR) corrected aortic AIx significantly decreases only in the combined-treatment group.
PMID:22421908 · one of two readings recorded this
heart-rate-corrected aortic augmentation index (AIx)
decreases, significantly decreases only in the combined-treatment group
Heart rate (HR) corrected aortic AIx significantly decreases only in the combined-treatment group.
PMID:22421908 · one of two readings recorded this
in-hospital myocardial infarction incidence
decreases, adjusted hazard ratio 0.35, 0.13 to 0.95, p = 0.038
Incidence of in-hospital MI was decreased from 30.0% in the placebo group to 13.1% in the curcuminoid group (adjusted hazard ratio 0.35, 0.13 to 0.95, p = 0.038).
PMID:22481014 · both readings recorded this
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
decreases, lower in the curcumin than in the placebo group
Not recorded as a finding: no outcome node for NT-proBNP
Postoperative C-reactive protein, malondialdehyde, and N-terminal pro-B-type natriuretic peptide levels were also lower in the curcumin than in the placebo group.
PMID:22481014 · both readings recorded this
arm circumference
no effect, remained statistically unchanged
Not recorded as a finding: no outcome node for arm circumference
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
body fat
no effect, remained statistically unchanged
Not recorded as a finding: the fat-mass node requires a DXA (or stated) method; this paper does not state how body fat was measured
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
body weight, BMI, waist/hip/arm circumference, body fat
no effect
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
hip circumference
no effect, remained statistically unchanged
Not recorded as a finding: no outcome node for hip circumference
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
total cholesterol, LDL cholesterol, HDL cholesterol, high-sensitivity C-reactive protein
no effect
However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).
PMID:22610853 · one of two readings recorded this
total cholesterol, LDL cholesterol, HDL cholesterol, high-sensitivity CRP
no effect
However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).
PMID:22610853 · one of two readings recorded this
waist circumference
no effect, remained statistically unchanged
Not recorded as a finding: no outcome node for waist circumference
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
weight, BMI, waist/hip/arm circumference, body fat
no effect
Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).
PMID:22610853 · one of two readings recorded this
serum adiponectin
increases, gradually elevated, significantly different from placebo by final visit
Levels of adiponectin, an anti-inflammatory cytokine, in the placebo-treated group were virtually unchanged, whereas those of the curcumin-treated group were gradually elevated and became significantly different from that of placebo-treated group at the final visit (9 months) (Table 2).
PMID:22773702 · both readings recorded this
AST, ALT, creatinine, bone mineral density (adverse-effect monitoring)
no effect, no significant differences between groups
We found no significant differences in the means of AST, ALT, creatinine, and BMD between the curcumin-treated and placebo-treated group.
PMID:22773702 · one of two readings recorded this
AST, ALT, creatinine, bone mineral density (safety)
no effect
We found no significant differences in the means of AST, ALT, creatinine, and BMD between the curcumin-treated and placebo-treated group.
PMID:22773702 · one of two readings recorded this
body weight and waist circumference
decreases
Interestingly, at the last follow-up visit (9 months after intervention), we noticed a slight reduction of mean body weight and WC from the group of subjects treated with curcumin.
PMID:22773702 · one of two readings recorded this
C-peptide
decreases, significantly lower in curcumin-treated group
Blood levels of C-peptide were found to be significantly lower in curcumin-treated group when compared with those of placebo group.
PMID:22773702 · both readings recorded this
HOMA-β (beta-cell function index)
increases, increasingly elevated, statistically significant at the final (9-month) visit
Not recorded as a finding: no_outcome_node -- no beta-cell-function node exists in the outcome list
shows that HOMA-β in the curcumin-treated group was increasingly elevated in all follow-up visits (at 3, 6, and 9 months) and became statistically significant at the final visit (9 months).
PMID:22773702 · one of two readings recorded this
HOMA-beta
increases
shows that HOMA-β in the curcumin-treated group was increasingly elevated in all follow-up visits (at 3, 6, and 9 months) and became statistically significant at the final visit (9 months).
PMID:22773702 · one of two readings recorded this
HOMA-β
increases, increasingly elevated, significant at final visit
shows that HOMA-β in the curcumin-treated group was increasingly elevated in all follow-up visits (at 3, 6, and 9 months) and became statistically significant at the final visit (9 months).
PMID:22773702 · one of two readings recorded this
incident type 2 diabetes diagnosis (ADA criteria)
decreases, 0% curcumin vs 16.4% placebo at 9 months
Not recorded as a finding: no outcome node for incident type 2 diabetes diagnosis
However, none of the subjects in the curcumin-treated group developed T2DM (Table 3).
PMID:22773702 · one of two readings recorded this
incident type 2 diabetes diagnosis
decreases, 0% curcumin vs 16.4% placebo at 9 months
However, none of the subjects in the curcumin-treated group developed T2DM (Table 3).
PMID:22773702 · one of two readings recorded this
onset of type 2 diabetes mellitus, ADA diagnostic criteria (FPG ≥126 mg/dL, OGTT 2h ≥200 mg/dL, or HbA1c ≥6.5%)
decreases, 19 subjects (16.4%) developed T2DM in the placebo group at 12 months vs none in the curcumin group
Not recorded as a finding: no_outcome_node -- no diabetes-incidence node exists in the outcome list
However, none of the subjects in the curcumin-treated group developed T2DM (Table 3).
PMID:22773702 · one of two readings recorded this
onset of type 2 diabetes mellitus
decreases, 19 subjects (16.4%) developed T2DM in placebo group at 12 months vs none in curcumin group
However, none of the subjects in the curcumin-treated group developed T2DM (Table 3).
PMID:22773702 · one of two readings recorded this
proinsulin/insulin ratio
no effect
Although not significant, proinsulin/insulin ratio showed a lower trend in the curcumin-treated group (Table 2).
PMID:22773702 · one of two readings recorded this
serum C-peptide
decreases, significantly lower in curcumin-treated group
Not recorded as a finding: no_outcome_node -- no C-peptide node exists in the outcome list
Blood levels of C-peptide were found to be significantly lower in curcumin-treated group when compared with those of placebo group.
PMID:22773702 · one of two readings recorded this
triglycerides
decreases, p = 0.018
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · both readings recorded this
lipoprotein lipase (LPL) activity
increases
Not recorded as a finding: no outcome node for LPL activity
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · one of two readings recorded this
lipoprotein lipase (LPL) activity
increases
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · one of two readings recorded this
serum total free fatty acids (FFAs)
decreases
Not recorded as a finding: no outcome node for free fatty acids
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · one of two readings recorded this
serum total free fatty acids (FFAs)
decreases
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · one of two readings recorded this
serum triglycerides
decreases, p = 0.018
Not recorded as a finding: fasting state not explicitly stated for this lipid/FFA panel measurement (only fasting glucose is explicitly described as fasting); CAT:outcome/serum-triglycerides requires a sample drawn after a stated fast
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · one of two readings recorded this
plasma, urine and peripheral-tissue curcumin concentration after oral administration
no effect, extremely low or undetectable even after large doses
However, an increasing number of animal and clinical studies show that the concentrations of CUR in blood plasma, urine, and peripheral tissues, if at all detectable, are extremely low even after large doses.
PMID:22996406 · one of two readings recorded this
calcitonin gene-related peptide (CGRP)
decreases
Serum CGRP was only decreased in the curcumin group (P < 0.001).
PMID:23038702 · both readings recorded this
high-sensitivity C-reactive protein (hs-CRP)
decreases, magnitude of reduction greater in curcumin group
Serum IL-8 and hs-CRP were significantly reduced in both groups but the magnitude of reduction was greater in the curcumin group (P < 0.001).
PMID:23038702 · both readings recorded this
interleukin-6 (IL-6)
no effect
No significant change was observed in serum IL-6.
PMID:23038702 · one of two readings recorded this
interleukin-6 (IL-6)
no effect
No significant change was observed in serum IL-6.
PMID:23038702 · one of two readings recorded this
interleukin-8 (IL-8)
decreases
Serum IL-8 and hs-CRP were significantly reduced in both groups but the magnitude of reduction was greater in the curcumin group (P < 0.001).
PMID:23038702 · both readings recorded this
pruritus severity and Dermatology Life Quality Index (DLQI)
IL-8 changes were a significant predictor of DLQI scores, p = 0.026
In the curcumin group, changes in serum IL-8 concentrations were found as the significant predictor of DLQI scores (P = 0.026) but none of the independent variables could predict pruritus scores.
PMID:23038702 · one of two readings recorded this
serum calcitonin gene-related peptide (CGRP)
decreases, decreased only in the curcumin group
Not recorded as a finding: no outcome node for CGRP
Serum CGRP was only decreased in the curcumin group (P<0.001).
PMID:23038702 · both readings recorded this
serum interleukin-6 (IL-6)
no effect
Not recorded as a finding: the only supporting sentence is an agentless passive that does not name the compound, so it cannot anchor a claim even though an interleukin-6 node exists
No significant change was observed in serum IL-6.
PMID:23038702 · both readings recorded this
serum interleukin-8 (IL-8)
decreases, magnitude of reduction greater in the curcumin group
Not recorded as a finding: no outcome node for IL-8
Serum IL-8 and hs-CRP were significantly reduced in both groups but the magnitude of reduction was greater in the curcumin group (P < 0.001).
PMID:23038702 · both readings recorded this
relapse in ulcerative colitis maintained on mesalamine/sulfasalazine background, assessed at 6 and 12 months (Cochrane review of a single 89-patient RCT)
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There was no statistically significant difference in relapse rates at 12 months.
PMID:23076948 · one of two readings recorded this
ulcerative colitis relapse rate at six months
decreases, RR 0.24, 95% CI 0.05 to 1.09, p = 0.06
Not recorded as a finding: this platform holds no node for the endpoint
Four per cent of patients in the curcumin group relapsed at six months compared to 18% of patients in the placebo group (RR 0.24, 95% CI 0.05 to 1.09; P = 0.06).
PMID:23076948 · one of two readings recorded this
hepatic fatty-acid accumulation / hypolipidic effect of curcumin
decreases, prevents fatty acid accumulation in hepatocytes
In combating liver diseases, it seems clear that curcumin exerts a hypolipidic effect, which prevents the fatty acid accumulation in the hepatocytes that may result from metabolic imbalances, and which may cause nonalcoholic steatohepatitis.
PMID:23303639 · one of two readings recorded this
cognitive function and plasma/CSF amyloid-beta, tau and phosphorylated tau, phase II AD clinical trial
no effect
Unfortunately, no significant improvement in cognitive function or changes in the levels of Aβ, total tau and phosphorylated tau in plasma and CSF were found (Table 1).
PMID:23303664 · one of two readings recorded this
organism lifespan, Drosophila melanogaster
increases, lifespan extension associated with increased SOD activity, decreased lipofuscin and malondialdehyde
The lifespan extension of Drosophila by curcumin supplementation was associated with increased superoxide dismutase (SOD) activity, and decreased lipofuscin and malondialdehyde levels.
PMID:23325575 · one of two readings recorded this
organism lifespan in model organisms (nematode, Drosophila, mouse) following curcumin or tetrahydrocurcumin exposure, narrated across independent studies with no pooled estimate
increases
Not recorded as a finding: a review that discusses its trials without pooling them
Nematodes grown on media containing curcumin showed a significantly increased lifespan by reducing the production of reactive oxygen species.
PMID:23325575 · one of two readings recorded this
organism lifespan, mouse (tetrahydrocurcumin from 13 months of age)
increases, significantly increased mean lifespan
Mice fed diets containing THC starting at the age of 13 months had significantly increased mean lifespan.
PMID:23325575 · one of two readings recorded this
organism lifespan, nematode (C. elegans)
increases, significantly increased lifespan by reducing reactive oxygen species production
Nematodes grown on media containing curcumin showed a significantly increased lifespan by reducing the production of reactive oxygen species.
PMID:23325575 · one of two readings recorded this
organism lifespan, pooled across nematode, Drosophila and mouse
increases, curcumin and THC increase mean lifespan of at least three model organisms
Recently, active research on curcumin with respect to aging and related traits in model organisms has demonstrated that curcumin and its metabolite, tetrahydrocurcumin (THC), increase mean lifespan of at least three model organisms: nematode roundworm, fruit fly Drosophila, and mouse.
PMID:23325575 · one of two readings recorded this
adipocyte differentiation and antioxidant activity
decreases, inhibits adipocyte differentiation; promotes antioxidant activities
Curcumin also has effects to inhibit adipocyte differentiation and to promote antioxidant activities.
PMID:23339049 · one of two readings recorded this
macrophage infiltration and NF-κB activation in adipose tissue
decreases, inhibits macrophage infiltration and NF-κB activation induced by inflammatory agents
In adipose tissue, curcumin inhibits macrophage infiltration and nuclear factor κB (NF-κB) activation induced by inflammatory agents.
PMID:23339049 · one of two readings recorded this
proinflammatory adipokine expression (TNFα, MCP-1, PAI-1) and adiponectin expression
decreases, reduces TNFα, MCP-1, PAI-1; induces adiponectin expression
Curcumin reduces the expression of the potent proinflammatory adipokines tumor necrosis factor-α (TNFα), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor type-1 (PAI-1), and it induces the expression of adiponectin, the principal anti-inflammatory agent secreted by adipocytes.
PMID:23339049 · one of two readings recorded this
antibody titres to Hsp27 (anti-Hsp27)
no effect
However, no significant change was observed in serum concentrations of anti-Hsp27 or anti-oxLDL (p > 0.05).
PMID:23494802 · both readings recorded this
antibody titres to oxidised LDL (anti-oxLDL)
no effect
However, no significant change was observed in serum concentrations of anti-Hsp27 or anti-oxLDL (p > 0.05).
PMID:23494802 · one of two readings recorded this
antibody titres to oxidized LDL (anti-oxLDL)
no effect
However, no significant change was observed in serum concentrations of anti-Hsp27 or anti-oxLDL (p > 0.05).
PMID:23494802 · one of two readings recorded this
serum pro-oxidant-antioxidant balance (PAB assay); antibody titres to Hsp27 (anti-Hsp27) and oxidized LDL (anti-oxLDL)
decreases, p = 0.044
Not recorded as a finding: this platform holds no node for the endpoint
Curcuminoid supplementation was associated with a significant decrease in PAB (p = 0.044).
PMID:23494802 · one of two readings recorded this
serum pro-oxidant-antioxidant balance (PAB)
decreases, significant decrease in PAB (p = 0.044), p = 0.044
Not recorded as a finding: this platform holds no node for the endpoint
Curcuminoid supplementation was associated with a significant decrease in PAB (p = 0.044).
PMID:23494802 · one of two readings recorded this
serum pro-oxidant-antioxidant balance (PAB)
decreases, p = 0.044
Curcuminoid supplementation was associated with a significant decrease in PAB (p = 0.044).
PMID:23494802 · one of two readings recorded this
HOMA-IR
decreases
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
serum leptin
decreases
Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.
PMID:24445038 · one of two readings recorded this
triglycerides
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
serum uric acid
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
triglyceride
decreases
Not recorded as a finding: fasting state not explicitly stated for this measurement
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
homeostasis model assessment insulin resistance (HOMA-IR)
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
homeostasis model assessment-insulin resistance (HOMA-IR)
decreases
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
total body fat
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin, and no measurement method is stated; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
visceral fat
decreases
Not recorded as a finding: no matching outcome node for visceral fat specifically (distinct from the general fat-mass node)
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · both readings recorded this
curcuminoid plasma pharmacokinetics (AUC0-12, Cmax, tmax) across four curcumin formulations, HPLC-MS/MS
increases, 45.9-fold higher relative appearance for CHC formulation vs unformulated standard curcumin (CS), n = 12
Not recorded as a finding: the comparison was against another active treatment
CHC showed a 45.9-fold higher relative appearance over standard and was significantly improved over CS, CP and CTR.
PMID:24461029 · one of two readings recorded this
plasma total curcuminoid appearance (AUC0-12, Cmax, tmax), HPLC-MS/MS
increases, CHC 45.9-fold higher relative appearance over CS; CP 7.9-fold higher over CS, n = 12
CHC showed a 45.9-fold higher relative appearance over standard and was significantly improved over CS, CP and CTR.
PMID:24461029 · one of two readings recorded this
plasma total curcuminoid (curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin) pharmacokinetics -- AUC0-12, Cmax, tmax -- by HPLC-MS/MS, across four formulations
increases, CHC showed a 45.9-fold higher relative appearance over standard and was significantly improved over CS, CP and CTR, n = 12
Not recorded as a finding: the comparison was against another active treatment
CHC showed a 45.9-fold higher relative appearance over standard and was significantly improved over CS, CP and CTR.
PMID:24461029 · one of two readings recorded this
time to maximum plasma concentration (tmax) across formulations
increases
There were significant differences between the time of maximum plasma concentrations (tmax) of the four products as shown by the results of a nonparametric Friedman's Test (χ2 = 8.5 p < 0.05).
PMID:24461029 · one of two readings recorded this
total curcuminoid AUC0-12 (plasma), HPLC-MS/MS
increases, CHC 45.9-fold higher than CS, n = 12
CHC showed a 45.9-fold higher relative appearance over standard and was significantly improved over CS, CP and CTR.
PMID:24461029 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF), hippocampus and frontal cortex (diabetic mice)
increases
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF), hippocampus/frontal cortex, mice
increases
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF) in hippocampus, frontal cortex and serum; protein oxidation (PO) and lipid peroxidation (LP) in hippocampus, frontal cortex and serum
no effect
Not recorded as a finding: this platform holds no node for the endpoint
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF) levels in hippocampus and frontal cortex of diabetic mice, and in sera of obese humans
increases
Not recorded as a finding: this platform holds no node for the endpoint
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF), sera (obese humans)
no effect
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
brain-derived neurotrophic factor (BDNF), serum, obese humans
no effect
Curcumin improved or restored BDNF levels to normal levels in DM, but curcumin did not have any effect on BDNF levels in sera of obese humans.
PMID:24476477 · one of two readings recorded this
lipid peroxidation (LP), hippocampus and frontal cortex (diabetic mice)
no effect
In hippocampus and FC of DM, hyperglycaemia and curcumin did not have effect on LP levels.
PMID:24476477 · one of two readings recorded this
lipid peroxidation (LP), hippocampus and frontal cortex, mice
no effect
In hippocampus and FC of DM, hyperglycaemia and curcumin did not have effect on LP levels.
PMID:24476477 · one of two readings recorded this
protein oxidation (PO), hippocampus and frontal cortex (diabetic mice)
decreases
Hyperglycaemia increased PO levels in hippocampus and FC, whereas curcumin decreased these levels in hippocampus but not in FC.
PMID:24476477 · one of two readings recorded this
protein oxidation (PO), hippocampus and frontal cortex, mice
decreases
Hyperglycaemia increased PO levels in hippocampus and FC, whereas curcumin decreased these levels in hippocampus but not in FC.
PMID:24476477 · one of two readings recorded this
Mini-Mental State Examination (MMSE) score change from baseline to follow-up in Alzheimer's disease patients (Baum et al. 2008 RCT, curcumin vs placebo, both arms also receiving background standardised gingko biloba extract)
no effect
Not recorded as a finding: the supporting sentence never names the compound
The authors did not observe any significant difference between curcumin and placebo.
PMID:24578620 · one of two readings recorded this
serum IL-1β (Biochip Array immunoassay)
decreases, p = 0.042
Not recorded as a finding: no outcome node for IL-1β
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum IL-1α, IL-2, IL-6, IL-8, IL-10, IFNγ, EGF, MCP-1, TNFα
no effect, did not alter serum concentrations
On the other hand, curcuminoids supplementation did not alter serum concentrations of IL-1 α, IL-2, IL-6, IL-8, IL-10, IFN γ, EGF, MCP-1, and TNF α (P > 0.05).
PMID:24678280 · one of two readings recorded this
serum IL-1α, IL-2, IL-8, IL-10, IFNγ, EGF and MCP-1 concentrations, multiplex Biochip Array Technology
no effect, did not alter serum concentrations
Not recorded as a finding: no_outcome_node -- none of these analytes has an entry in the outcome list
On the other hand, curcuminoids supplementation did not alter serum concentrations of IL-1 α, IL-2, IL-6, IL-8, IL-10, IFN γ, EGF, MCP-1, and TNF α (P > 0.05).
PMID:24678280 · one of two readings recorded this
serum IL-1β, IL-4, VEGF
decreases, significantly reduced
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum IL-1alpha, IL-2, IL-6, IL-8, IL-10, IFN-gamma, EGF, MCP-1, TNF-alpha
no effect
curcuminoids supplementation did not alter serum concentrations of IL-1 α, IL-2, IL-6, IL-8, IL-10, IFN γ, EGF, MCP-1, and TNF α (P > 0.05).
PMID:24678280 · one of two readings recorded this
serum IL-1beta
decreases, p = 0.042
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum IL-4 (Biochip Array immunoassay)
decreases, p = 0.008
Not recorded as a finding: no outcome node for IL-4
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum IL-4
decreases, p = 0.008
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum interleukin-1β (IL-1β) concentration, multiplex Biochip Array Technology
decreases, significantly reduced, p = 0.042
Not recorded as a finding: no_outcome_node -- IL-1β has no entry in the outcome list
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum interleukin-4 (IL-4) concentration, multiplex Biochip Array Technology
decreases, significantly reduced, p = 0.008
Not recorded as a finding: no_outcome_node -- IL-4 has no entry in the outcome list
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum vascular endothelial growth factor (VEGF) concentration, multiplex Biochip Array Technology
decreases, significantly reduced, p = 0.03
Not recorded as a finding: no_outcome_node -- VEGF has no entry in the outcome list
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum VEGF (Biochip Array immunoassay)
decreases, p = 0.03
Not recorded as a finding: no outcome node for VEGF
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
serum VEGF
decreases, p = 0.03
Dietary supplementation with curcuminoids was found to be associated with significantly reduced serum levels of IL-1 β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.03).
PMID:24678280 · one of two readings recorded this
inflammatory biomarker panel (IL-4, IL-6, TNF-alpha, TGF-beta, hs-CRP, ESR), between-group
no effect, n = 40
Comparison of the magnitude of changes in the evaluated inflammatory biomarkers did not indicate any significant difference between the study groups (p>0.05).
PMID:25050518 · one of two readings recorded this
magnitude of change in all evaluated inflammatory biomarkers, curcuminoid vs placebo
no effect, no significant difference between the study groups
Comparison of the magnitude of changes in the evaluated inflammatory biomarkers did not indicate any significant difference between the study groups (p>0.05).
PMID:25050518 · one of two readings recorded this
serum IL-4, IL-6 and hs-CRP
decreases, significantly reduced in the curcuminoid group by end of trial
Serum concentrations of IL-4 (p=0.001), IL-6 (p=0.006) and hs-CRP (p=0.004) were significantly reduced in the curcuminoid group whilst serum levels of TNF-α and TGF-β and mean ESR remained unaltered by the end of trial (p>0.05).
PMID:25050518 · one of two readings recorded this
serum IL-4, IL-6, TNF-α and TGF-β, placebo group
decreases, significantly reduced in the placebo group
In the placebo group, serum concentrations of IL-4 (p=0.001), IL-6 (p=0.003), TNF-α (p=0.003) and TGF-β (p=0.005) were significantly reduced but mean hs-CRP and ESR values remained statistically unchanged (p>0.05).
PMID:25050518 · one of two readings recorded this
serum IL-4, IL-6, TNF-α, TGF-β, hs-CRP and mean ESR at baseline and end of 6-week trial
no effect, n = 40
Not recorded as a finding: the result compares a group with itself, not with a control
Comparison of the magnitude of changes in the evaluated inflammatory biomarkers did not indicate any significant difference between the study groups (p>0.05).
PMID:25050518 · one of two readings recorded this
serum inflammatory biomarkers (IL-4, IL-6, TNF-α, TGF-β, hs-CRP) and erythrocyte sedimentation rate, magnitude-of-change comparison, curcuminoids vs placebo
no effect, no significant difference in magnitude of change between curcuminoid and placebo groups
Not recorded as a finding: the supporting sentence never names the compound
Comparison of the magnitude of changes in the evaluated inflammatory biomarkers did not indicate any significant difference between the study groups (p>0.05).
PMID:25050518 · one of two readings recorded this
serum TNF-α, TGF-β and mean ESR, curcuminoid group
no effect, remained unaltered by end of trial
Serum concentrations of IL-4 (p=0.001), IL-6 (p=0.006) and hs-CRP (p=0.004) were significantly reduced in the curcuminoid group whilst serum levels of TNF-α and TGF-β and mean ESR remained unaltered by the end of trial (p>0.05).
PMID:25050518 · one of two readings recorded this
triglycerides
decreases, a reduction of 65 mg/dL
The triglyceride-lowering effect, a reduction of 65 mg/dL, was also found in this study.
PMID:25131839 · both readings recorded this
body weight and fasting glucose homeostasis
The intake of the curcumin extract of 1890 mg/day for 12 weeks was associated with lipid-lowering effect but did not improve weight and glucose homeostasis in the patients with metabolic syndrome.
PMID:25131839 · one of two readings recorded this
total cholesterol / HDL ratio, male and female subgroups
decreases
In subgroups analysis, the consumption of curcumin may have a lowering cholesterol effect in male patients and an increasing HDL-C effect in female patients, both of which result in a decrease of T-Chol/HDL-C ratio.
PMID:25131839 · one of two readings recorded this
weight and glucose homeostasis
no effect
The intake of the curcumin extract of 1890 mg/day for 12 weeks was associated with lipid-lowering effect but did not improve weight and glucose homeostasis in the patients with metabolic syndrome.
PMID:25131839 · one of two readings recorded this
FEV1 and FVC (spirometric volumes)
no effect, remained comparable between the groups
Although FEV1 and FVC remained comparable between the groups, there was a greater effect of curcuminoids vs. placebo in improving FEV1/FVC (p=0.002).
PMID:25268878 · one of two readings recorded this
FEV1/FVC ratio
increases, greater effect of curcuminoids vs placebo in improving FEV1/FVC, p = 0.002
Although FEV1 and FVC remained comparable between the groups, there was a greater effect of curcuminoids vs. placebo in improving FEV1/FVC (p=0.002).
PMID:25268878 · both readings recorded this
FEV1, FVC
no effect
Although FEV1 and FVC remained comparable between the groups, there was a greater effect of curcuminoids vs. placebo in improving FEV1/FVC (p=0.002).
PMID:25268878 · one of two readings recorded this
IL-6, IL-8, TNF-alpha, TGF-beta, substance P, hs-CRP, CGRP, MCP-1
unclear
Curcuminoids were also significantly more efficacious compared to placebo in modulating all assessed inflammatory mediators: IL-6 (p<0.001), IL-8 (p=0.035), TNFα (p<0.001), TGFβ (p<0.001), substance P (p=0.016), hs-CRP (p<0.001), CGRP (p<0.001) and MCP-1 (p<0.001).
PMID:25268878 · one of two readings recorded this
serum IL-6, IL-8, TNFα, TGFβ, substance P, hs-CRP, CGRP and MCP-1 concentrations, curcuminoids vs placebo
Not recorded as a finding: the direction is carried only as a signed number
Curcuminoids were also significantly more efficacious compared to placebo in modulating all assessed inflammatory mediators: IL-6 (p<0.001), IL-8 (p=0.035), TNFα (p<0.001), TGFβ (p<0.001), substance P (p=0.016), hs-CRP (p<0.001), CGRP (p<0.001) and MCP-1 (p<0.001).
PMID:25268878 · one of two readings recorded this
serum IL-6, IL-8, TNFα, TGFβ, substance P, hs-CRP, CGRP and MCP-1
unclear, significantly more efficacious in modulating all assessed inflammatory mediators; direction of modulation not stated in words
Curcuminoids were also significantly more efficacious compared to placebo in modulating all assessed inflammatory mediators: IL-6 (p<0.001), IL-8 (p=0.035), TNFα (p<0.001), TGFβ (p<0.001), substance P (p=0.016), hs-CRP (p<0.001), CGRP (p<0.001) and MCP-1 (p<0.001).
PMID:25268878 · one of two readings recorded this
spirometric FEV1, FVC and FEV1/FVC ratio
increases, p = 0.002
Not recorded as a finding: this platform holds no node for the endpoint
Although FEV1 and FVC remained comparable between the groups, there was a greater effect of curcuminoids vs. placebo in improving FEV1/FVC (p=0.002).
PMID:25268878 · one of two readings recorded this
sustained attention performance
increases
Not recorded as a finding: outcome node requires a named validated instrument; the abstract reports only 'sustained attention tasks' without naming the instrument used
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
working memory performance
increases
Not recorded as a finding: outcome node requires a named validated instrument; the abstract reports only 'working memory tasks' without naming the instrument used
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
general fatigue
increases
Not recorded as a finding: outcome node requires a named validated fatigue self-report instrument; the abstract does not name one
Working memory and mood (general fatigue and change in state calmness, contentedness and fatigue induced by psychological stress) were significantly better following chronic treatment.
PMID:25277322 · one of two readings recorded this
hematological safety measures
no effect, no effect
Curcumin was associated with significantly reduced total and LDL cholesterol and had no effect on hematological safety measures.
PMID:25277322 · both readings recorded this
mood (general fatigue, state calmness, contentedness) following chronic treatment
increases
Working memory and mood (general fatigue and change in state calmness, contentedness and fatigue induced by psychological stress) were significantly better following chronic treatment.
PMID:25277322 · one of two readings recorded this
mood (general fatigue, state calmness, contentedness, stress-induced fatigue)
increases, significantly better following chronic treatment
Working memory and mood (general fatigue and change in state calmness, contentedness and fatigue induced by psychological stress) were significantly better following chronic treatment.
PMID:25277322 · one of two readings recorded this
sustained attention performance, task-based
increases
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
sustained attention task performance
increases, significantly improved performance on sustained attention tasks compared with placebo
Not recorded as a finding: instrument_not_stated -- the sustained-attention node requires a named validated vigilance or cancellation task; the abstract states only 'sustained attention...tasks' without naming one
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
total and LDL cholesterol
decreases, significantly reduced
Curcumin was associated with significantly reduced total and LDL cholesterol and had no effect on hematological safety measures.
PMID:25277322 · both readings recorded this
total cholesterol
decreases, significantly reduced total ... cholesterol
Not recorded as a finding: no_outcome_node span issue -- the only supporting sentence reads 'total and LDL cholesterol', in which 'total cholesterol' is not a contiguous substring, so it cannot be anchored independently of LDL cholesterol
Curcumin was associated with significantly reduced total and LDL cholesterol and had no effect on hematological safety measures.
PMID:25277322 · both readings recorded this
working memory performance, task-based
increases
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
working memory task performance
increases, significantly improved performance on working memory tasks compared with placebo; also significantly better following chronic treatment
Not recorded as a finding: instrument_not_stated -- the working-memory node requires a named validated instrument; the abstract does not name one
One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.
PMID:25277322 · one of two readings recorded this
C-reactive protein (CRP)
decreases
Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.
PMID:25374024 · both readings recorded this
serum adipocyte-fatty acid binding protein (A-FABP), immunoassay
decreases
Not recorded as a finding: no outcome node for A-FABP
Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.
PMID:25374024 · one of two readings recorded this
serum adipocyte-fatty acid binding protein (A-FABP)
decreases
Not recorded as a finding: no matching outcome node for adipocyte-fatty acid binding protein
Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.
PMID:25374024 · one of two readings recorded this
serum adipocyte-fatty acid binding protein (A-FABP)
decreases
Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels.
PMID:25374024 · one of two readings recorded this
serum superoxide dismutase (SOD) activity
increases
Curcuminoids supplementation also significantly increased serum superoxide dismutase (SOD) activity.
PMID:25374024 · one of two readings recorded this
HDL cholesterol
increases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
triglycerides
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
HDL-cholesterol
increases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
LDL cholesterol (LDL-C)
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · one of two readings recorded this
LDL-cholesterol
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · one of two readings recorded this
lipoprotein(a) [Lp(a)]
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · one of two readings recorded this
Sources cited
61 papers
- Subject
- curcumin
- Findings
- 139
- Papers
- 61
Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.record2026PMID:413887441 finding
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.record2026PMID:421234393 findings
Effects of Curcumin Supplementation on Inflammatory Biomarkers in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:427970111 finding
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:421711916 findings
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.record2026PMID:426562684 findings
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.record2025PMID:4109655612 findings
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.record2025PMID:382131883 findings
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.record2025PMID:407599972 findings
Effect of curcumin on inflammatory markers and disease activity in patients with rheumatoid arthritis: A meta-analysis.record2025PMID:413277191 finding
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.record2025PMID:411683132 findings
Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial.record2025PMID:410537711 finding
Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.record2025PMID:405793151 finding
Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.record2025PMID:406472691 finding
Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.record2024PMID:396835702 findings
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway.record2024PMID:390539322 findings
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.record2024PMID:382329066 findings
Curcumin suppresses RANKL-induced osteoclast precursor autophagy in osteoclastogenesis by inhibiting RANK signaling and downstream JNK-BCL2-Beclin1 pathway.record2024PMID:371790101 finding
Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression.record2024PMID:389658662 findings
Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis.record2024PMID:380360151 finding
Meta-analysis of the effect of curcumin supplementation on skeletal muscle damage status.record2024PMID:390085002 findings
The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials.record2024PMID:379809422 findings
The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses.record2024PMID:389453541 finding
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.record2023PMID:3703789110 findings
Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials.record2023PMID:370339301 finding
The effect of curcumin supplementation on weight loss and anthropometric indices: an umbrella review and updated meta-analyses of randomized controlled trials.record2023PMID:368986351 finding
The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.record2023PMID:354757142 findings
A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms.record2022PMID:354581701 finding
Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.record2022PMID:360587631 finding
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.record2022PMID:361597924 findings
The effect of curcumin supplementation on delayed-onset muscle soreness, inflammation, muscle strength, and joint flexibility: A systematic review and dose-response meta-analysis of randomized controlled trials.record2022PMID:355746271 finding
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.record2022PMID:353459913 findings
The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis.record2022PMID:362055861 finding
Curcumin Attenuates Both Acute and Chronic Immune Nephritis.record2020PMID:321433111 finding
Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis.record2020PMID:321018711 finding
The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.record2020PMID:317997142 findings
Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis.record2019PMID:314329951 finding
Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:291858081 finding
Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:309418141 finding
The effect of curcumin supplementation on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:314259421 finding
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2019PMID:312495283 findings
The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:314236261 finding
The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:304029902 findings
Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.record2018PMID:292914291 finding
Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis.record2018PMID:296223431 finding
Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.record2018PMID:305272532 findings
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.record2018PMID:301561453 findings
Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress.record2017PMID:280700181 finding
Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis.record2017PMID:288804131 finding
Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials.record2016PMID:270257861 finding
Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials.record2016PMID:273927421 finding
Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.record2016PMID:274703992 findings
Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.record2016PMID:275336491 finding
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.record2016PMID:272708726 findings
Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.record2015PMID:256188001 finding
Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.record2015PMID:260663353 findings
Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.record2014PMID:253740244 findings
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.record2014PMID:244450383 findings
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.record2013PMID:229304033 findings
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.record2013PMID:226108537 findings
Curcumin extract for prevention of type 2 diabetes.record2012PMID:227737021 finding
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.record2012PMID:220994251 finding
Other names
8 names
Resolves to: curcumin
- Also called
- C.I. 75300C.I. Natural Yellow 3DiferuloylmethaneE 100Kacha haldiNatural yellow 3Turmeric yellow
- Systematic name
- (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione